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Résumé 
Contexte: À date, il existe peu de données sur l’adhésion, la persistance et les 
coûts associés aux antidépresseurs selon le type d’assurance médicament (privé 
ou public). 
Objectif: Comparer selon le régime d’assurance médicament (privé ou public), 
l'adhésion, la persistance et les coûts des antidépresseurs.  
Méthodes de recherche: Une étude de cohorte appariée a été réalisée en utilisant 
des bases de données du Québec. 
Sujets: Nous avons sélectionné 194 patients assurés par un régime privé et 1923 
patients assurés par le régime public de la Régie de l’assurance maladie du 
Québec (RAMQ) (18-64 ans) qui ont rempli au moins une ordonnance pour un 
antidépresseur entre décembre 2007 et septembre 2009. 
Mesures: L’adhésion, mesurée sur une période d’un an, a été estimée en utilisant 
le proportion of prescribed days covered (PPDC). Un modèle de régression linéaire 
a été utilisé afin d’estimer la différence moyenne en PPDC entre les patients 
assurés par un régime privé et ceux assurés par le régime public de la RAMQ. La 
persistance a été comparé entre ces deux groupes avec un modèle de régression 
de survie Cox, et le coût mensuel d'antidépresseurs ($ CAN) a été comparé entre 
ces deux groupes en utilisant un modèle de régression linéaire. 
Résultats: Le PPDC parmi les patients assurés par un régime privé était de 86,4% 
(intervalle de confiance (IC) 95%: 83,3%-89,5%) versus 81,3% (IC 95%: 80,1%-
82,5%) pour les patients assurés par le régime public de la RAMQ, pour une 
différence moyenne ajustée de 6,7% (IC 95%: 3,0%-10,4%). La persistance après 
un an parmi les patients assurés par un régime privé était de 49,5% versus 18,9% 
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pour les patients assurés par le régime public de la RAMQ (p <0,001), et le rapport 
de risque ajusté était de 0,48 (IC 95%: 0,30-0,76). Comparativement aux patients 
assurés par le régime public de la RAMQ, les patients ayant une assurance privée 
ont payé 14,94 $ CAD (95% CI: $12,30-$17,58) de plus par mois en moyenne pour 
leurs antidépresseurs. 
Conclusion: Les patients assurés par un régime privé avaient une meilleure 
adhésion, persistance, mais avaient aussi un plus haut coût pour leurs 
antidépresseurs que ceux assurés par le régime public de la RAMQ. Cette 
différence de coûts peut être due aux différentes exigences de paiement en 
pharmacie entre les deux régimes ainsi qu’aux limites des honoraires des 
pharmaciens imposés par le régime public.  
Mots-clés : antidépresseurs, adhésion, coût, médicament, étude rétrospective, 
assurance santé PDC, PPDC 
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Abstract 
Background: The influence of the type of drug insurance on adherence, 
persistence and cost of antidepressants is not well known. 
Objective: To compare adherence, persistence and cost of antidepressants in 
patients with private and public drug insurance.  
Research Design: A matched cohort study was conducted using prescription 
claims databases from Quebec, Canada.  
Subjects: 194 privately and 1923 publicly insured patients (18-64 years) who filled 
at least one prescription for an antidepressant between December 2007 and 
September 2009.  
Measures: Adherence over one year was estimated using the proportion of 
prescribed days covered (PPDC). The difference in mean PPDC between patients 
with private and public drug insurance was estimated with a linear regression 
model. Persistence was compared between the groups with a Cox regression 
model, and the monthly cost of antidepressants (CAD$) was compared between 
the two groups using linear regression.  
Results: The PPDC was 86.4% (95% CI: 83.3-89.5) in patients with private and 
81.3% (95%CI: 80.1-82.5) in patients with public drug insurance and the adjusted 
mean difference was 6.7% (95% CI: 3.0-10.4). Persistence was 49.5% in patients 
with private and 18.9% in patients with public drug insurance at one year 
(p<0.001), and the adjusted hazard ratio was 0.48 (95%CI: 0.30-0.76). Patients 
privately insured paid 14.94$ CAD (95% CI: 12.30; 17.58) more per month on 
average for their antidepressants. 
P a g e  | vi 
Conclusion: Better adherence and persistence and higher costs were observed in 
privately insured patients. Cost difference might be due to different pharmacy 
payment requirements and pharmacists’ honorary restrictions under the public 
plan. 
Keywords: antidepressant agents, medication adherence, drug costs, 
retrospective studies, insurance health PDC, PPDC 
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Preface 
This thesis consists of nine chapters including an introduction, objectives, a 
review of the literature, a methodology and a results section, the manuscript 
submitted in a scientific journal and a discussion section. The chapters are then 
followed by a bibliography, supplementary tables and appendices.  
The introduction provides the rationale and objectives of the study. It is then 
followed by the review of the literature which covers the main aspects of the study 
with an emphasis on adherence and persistence to antidepressants. The 
methodology and discussion chapters are a more detailed version on those found 
in the manuscript. The chapter on the results presents additional findings not 
reported in the manuscript. The discussion and conclusion summarizes the results 
and proposes future research interests. Lastly the bibliography covers all articles 
cited.  
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Chapter 1: Introduction 
Health expenditures in Canada have increased considerably over the last 
two decades, reaching $192 billion in 2010.1 Due to this increasing demand and 
cost for health services, the private sector in the universal Canadian health care 
system is receiving considerable attention. As such, assessing the effectiveness of 
private versus public health care services should be guided by scientific data which 
is currently lacking. In the province of Quebec, the public and private debate is 
drawing much attention. Surprisingly, in spite of the increasingly high cost, 
medications are rarely of concern. The Quebec universal drug insurance plan 
administered by the Régie de l’assurance maladie du Quebec (RAMQ) is the only 
universal plan in Canada that is based on a private and public partnership. Since 
January 1, 1997, it is mandatory for all residents of Quebec to have drug insurance 
coverage.2 Those that do not have access to a collective drug insurance plan 
through their employer or their spouse’s employer are automatically covered by the 
RAMQ’s public drug insurance plan for their medications, which represents 43% of 
the Quebec population.2
The cost of the public portion of the Quebec universal drug insurance plan 
(i.e. the RAMQ’s public drug plan) has been increasing steadily since its inception, 
escalating from 1.12 billion dollars in 1997 to more than 2.58 billion dollars in the 
RAMQ latest report in 2006.2 While several causes might have contributed to this 
increase, non-optimal use of drugs due to physician non-adherence to treatment 
guidelines, or patient non-adherence to the prescribed therapy, is certainly one of 
the contributing factors. Indeed, several studies have demonstrated a large gap 
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between actual use of drugs and guidelines in the treatment of chronic and acute 
diseases.3-19
It is important to note that the vast majority of Canadian studies on the 
impact of non-optimal drug use have been conducted among patients covered by 
public drug insurance plans. Drug use research among publicly covered patients 
has been greatly facilitated by access to medication data recorded in several 
provincial computerized administrative databases, such as the RAMQ, and thus 
can be easily linked to other medical services databases (outpatient’s visits, 
emergency department visits, hospitalizations) for the purposes of 
pharmacoepidemiologic research.  
On the other hand, research on the usage of prescription drugs among 
patients covered by private drug insurance programs in Canada is almost 
nonexistent. This is mainly due to the absence of computerized drug databases 
that can be easily linked to other health databases. This leaves researchers in the 
dark with respect to the discrepancies between these two subpopulations as to the 
usage of drugs, the impact that their use on patient health and the associated costs 
on the health care system.  
Due to the lack of computerized drug information on individuals covered by 
a private drug insurance program, we have recently developed a computerized 
registry called reMed. This registry stores data related to prescription drugs for 
residents in Quebec less than 65 years of age who are covered by a private drug 
insurance program. This registry is based upon the data that are purchased from 
the community pharmacies computer services provider (CSP), who manage the 
data transmission that is required for drug reimbursement by the private insurance 
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companies. One of the great advantages of reMed is that it contains the patient 
medical insurance number that allows the linkage of reMed to other Quebec 
computerized medical services databases.  
 To our knowledge, the Quebec public and private drug insurance programs 
have never been formally compared in terms of the usage of drugs, adherence, 
persistence, use of generics and the associated costs. We’ve decided to start 
within the context of antidepressants given the prevalent nature of depression as 
well as the heavy burden of this disease. Canadian public health authorities have 
reported that 5.8% of Canadians are taking antidepressants.20 Furthermore, it is 
estimated that 14.4% of Quebec adults under a public drug insurance plan are 
taking an antidepressant.21 The indications for antidepressants incur a heavy 
economic burden, moreover it is well documented that major depressive disorders 
alone is one of the most burdensome illnesses in Canada with a lifetime 
prevalence estimated at 10.8%.22
A number of studies conducted in the United States (US) have compared 
patients with private and public drug insurance.23,24 Although not looking at 
antidepressants in particular, these studies have found that privately insured 
patients tend to use newer and more expensive medications, while using less 
generic medications than publicly insured patients. In addition, some US studies 
have found that patient’s adherence to essential medications might differ according 
to the level of restriction of drug formularies and these restrictions might increase 
the need for health care services.25-28Furthermore, it is often difficult to generalize 
US or studies conducted in other countries to that of the Canadian context. This is 
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primarily due to the differences in socioeconomic status present in the US between 
publicly and privately insured people. 
From what we have learned from the literature comparing private and public 
drug insurances and from the existing differences between the private and public 
drug programs, namely larger coverage of newer medications and less 
reimbursement restrictions from the private side, we hypothesized that patients 
covered by a private drug insurance program might more often use newer and 
more expensive drugs. In comparing the RAMQ and reMed, i.e. public vs. private, 
we planned a study examining if differences were present in adherence and 
persistence with antidepressants. Drug costs as well as the use of generics were 
also compared between these two drug insurance plans. 
This study provides evidence on comparative patterns of behavior and 
expenditures between private and public drug coverage in a context where both 
plans coexist and are interdependent. 
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Chapter 2: Objectives & hypotheses 
2.0 General Objective  
To compare adherence, persistence and cost of antidepressants in patients 
with private and public drug insurance. 
2.1 Specific objectives  
1. To Compare adherence to antidepressants in patients with private and 
public drug insurance using the proportions days covered (PDC) and the 
proportion of prescribed days covered (PPDC) measures for all users and 
new users of antidepressants 
2. To compare persistence to antidepressants for new users only in patients 
with private and public drug insurance. 
3. To compare monthly cost of antidepressant subclasses in patients with 
private and public drug insurance. 
4. To compare cost of 30 day prescriptions of antidepressant subclasses and 
individual drugs in patients with private and public drug insurance. 
5. To compare generic and brand name use of antidepressants in patients with 
private and public drug insurance. 
2.2 Hypothesis  
Adherence, persistence, cost and brand name use of antidepressants will be 
higher in patients with private drug insurance.  
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Chapter 3: Literature review 
This chapter will review the different drug insurance plans in Quebec as well 
as the prevalence, economic burden and pharmacology of antidepressants.  
This chapter also encompasses a review of the guidelines of the treatment of major 
depression as well as a literature review of adherence, persistence and cost of 
antidepressants. These studies were identified with PubMed using the following 
keywords: antidepressants, adherence, persistence, cost, compliance, predictors, 
use, generic, medication, and depression. Only observational studies which 
assessed adherence, persistence or cost of antidepressants were included in the 
present review. 
3.1 Prevalence and economic burden of antidepressants 
Antidepressants are widely prescribed in the Canadian population. 
Estimates in Canada have shown that 5.8% of the population were on 
antidepressants in 2005.20 Moreover 14.4% of the Quebec population under the 
RAMQ medication insurance plan have been reported to use an antidepressant 
according to 2009 estimates.21
Antidepressants are primarily prescribed for the treatment of mood disorders 
and anxiety; however their use has been extended too many other diseases which 
are not necessarily approved as an indication (see details below).21 This has led to 
a wider and often non optimal use of this drug class which has also contributed to 
the economic burden of the diseases treated with antidepressants.29,30
P a g e  | 7 
The annual cost of antidepressant usage has been estimated at 128.8 million 
dollars (CAN) in 2009 for the adult population who are publicly insured in 
Quebec.21
3.2 Pharmacology and indications of antidepressants
Antidepressants are classified on the basis of their chemical structures and 
neuropharmacological effects. There are five main classes of antidepressants: First 
generation antidepressants are known as tricyclic and related cyclic compounds 
(TCA) and monoamineoxidase inhibitors (MAOI). Second generation 
antidepressants are known as selective serotonin re-uptake inhibitors (SSRI), 
serotonin norepinephrine reuptake inhibitors (SNRI) and atypical antidepressants 
(see Appendix). Although second generation antidepressants have similar efficacy 
to first generation antidepressants, TCA`s and MAOI`s are less commonly used 
due to their higher toxicity in overdose.31
The TCAs were the first group of antidepressants developed in 1950s. This 
category of antidepressants is known for its 3 ring structure with a side chain amine 
attached to the central ring. TCAs block the reuptake of norepinephrine (NE) 
and/or serotonin (5-HT) into noradrenergic and /or serotonergic nerve terminals, 
respectively by specific interactions with their plasma membrane transporters. The 
consequence of this inhibition is prolonged stimulation of NE and/or 5-HT receptors 
due to the NE and 5-HT released from these neurons not being rapidly terminated. 
In addition to inhibiting NE and 5HT reuptake the TCAs block muscarinic 
cholinergic receptors, alpha1 adrenergic receptors, and histamine H1 receptors as 
well which underlie many of their side effects.32
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MAOI compound are inhibitors of MAO and are not selective therefore inhibit 
both MAO-a and MAO-b. These two enzyme are distinct gene products where 
MAO-a is responsible for catabolism of 5-HT, NE, and tyramine and MAO-b is 
responsible for the catabolism of dopamine and tyramine. These enzymes facilitate 
inward directed transporter activity thus inhibition of MAO causes increase in levels 
of monoamine concentration in the cytosol of the nerve terminal.32
SSRIs work by selectively preventing the reuptake of serotonin by the 
presynaptic neuron, thus maintaining higher levels of 5-HT in the synapse. SNRI`s 
however work by inhibiting the reuptake of the neurotransmitters serotonin and 
norepinephrine. This results in an increase in the extracellular concentrations of 
serotonin and norepinephrine and therefore an increase in neurotransmission. This 
is done without the nonspecific, side effect-inducing interactions of TCAs.32,33
Atypical antidepressants were introduced during the same period as the 
selective serotonin reuptake inhibitors (SSRIs). These include bupropion, which 
has  primarily a dopaminergic effect, and trazodone, which is structurally similar to 
the tricyclic antidepressants (TCAs) but has a primary serotonergic mechanism.32
Although there are many indications for the use of antidepressants, they are 
primarily prescribed for depressive disorders such as major depressive disorder 
however anxiety disorders as well are often treated with antidepressants.21 A 
recent report on antidepressant use in Quebec publically insured adults showed 
that antidepressants were primarily prescribed for major depressive disorder which 
represented 14.7% followed by anxiety disorders representing 14.1% of 
antidepressant prescriptions.21 All the indications for antidepressants are listed in 
Table 1 below. 
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Table 1. Indications of use of antidepressants in mental and non-mental 
health conditions
Indications for mental health conditions
Depression29
Anxiety29
Schizophrenia and other psychotic disorders29
Personality disorders29
Adjustment disorders29
Eating disorders34
Insomnia35
Substance related disorders29
Attention deficit/conductive/disruptive behavior disorders
29
Delirium/dementia/amnesia and cognitive disorders29
Migraines30
Impulse control disorders not elsewhere classified29
Indications for non- mental health conditions
Fibromyalgia30
Connective tissue diseases30
Nervous system disorders29
Female genital disorders29
Chronic pain disorders29
Intervertebral disc disorders and other back problems29
Premature ejaculation
30
Tobacco cessation36
3.3 Main indications: Major depressive disorder and generalized anxiety 
disorder 
Major depressive disorder is a mental health disorder characterized by one 
or more major depressive episodes. These episodes are characterized by a 
depressed mood or a lack of interest or pleasure for all or almost all regular 
activities for duration of at least two weeks and are accompanied with at least five 
other depressed symptoms (Appendix II).33,37 Canadian estimates report a lifetime 
prevalence of 10.8% for major depressive episodes.22 Furthermore according to 
the Global Burden Disease study major depressive disorder is one of leading 
causes of disability.21
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Anxiety disorders are considers common disorders. Canadian estimates on 
one year prevalence of anxiety disorders are 12%.38 Generalized anxiety disorder 
is characterized by excessive worry and anxiety that is difficult to control and 
causes significant distress and impairment for the majority of at least six months.39
Generalized anxiety disorder is most often with onset during adulthood and a 
chronic course 40-43 and can lead to significant impairments in role functioning, 
diminished quality of life, and high health care costs.42 44 This disorder can be 
effectively treated with medication, psychotherapy, or a combination of the two 
modalities. 
3.3.1 Guidelines for treatment of major depressive disorders 
According to Canadian guidelines treatment of major depression can be 
viewed as consisting of two phases; the first is the acute phase which is the period 
from the start of treatment until an acceptable response has been obtained.
45
Depending on symptom improvement, acute phase treatment may extend 
anywhere from eight to twelve weeks.45 The ultimate goal of this phase is to reach 
remission or 50% reduction in symptoms or on a validated depression scale. This 
is then followed by the maintenance phase which will ultimately have as a goal to 
minimize the risk of relapse and recurrence.45 Guidelines recommend continuing 
maintenance phase treatment for six to 24 months and sometimes more at the 
required dose for achieving remission.46 Clinicians thus focus on resolving any 
residual symptoms, treating comorbid conditions, returning to full pre-morbid 
functioning and preventing return of symptoms. In everyday practice, physicians 
examine whether patients no longer meet the criteria for major depressive 
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episodes.47 Figure 1 outlines an algorithm for managing limited improvement with 
first line antidepressants.  
Treatments for major depressive disorder include SSRI, SNRI, TCA’s, 
MAOI’s and certain atypical antidepressants.45,48 First generation antidepressants, 
i.e. TCA and MAOI inhibitors are less commonly used due to their reduced risk 
benefit profile. In treatment resistant depression (TRD) commonly defined as lack 
of improvement or <20% reduction in depression scores following trials of two or 
more antidepressants, add-on treatments are often prescribed.45,48-50 In severe 
depression, guidelines strongly recommend that the use of electroconvulsive 
therapy (ECT) should be included in the first line treatment together with 
antidepressants and psychotherapy. Often if the depression has psychotic 
features, antipsychotics will also be prescribed.50
Ultimately the choice of therapeutic strategies should be personalized to 
each patient’s characteristics, previous response to antidepressants, side effect 
profile, comorbidities and cost.
37,45
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Figure 1. Algorithm for managing limited improvement with first line 
antidepressant. From Lam et al.51
3.3.2 Guidelines for the treatment of generalized anxiety disorder 
First line treatments for generalized anxiety disorder are SSRI or SNRI 
antidepressants.52 If effective, guidelines stress continuing SSRI or SNRI therapy 
for 12 months. The time necessary for a clinically meaningful response for an SSRI 
varies, however averages typically at four weeks.  If the patient has not shown 
signs of improvement after six to eight weeks on an acceptable dose, the 
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medication should be tapered off and a different medication should be tried.52 Non-
response after adequate SSRI trials can be followed by a different SSRI, followed 
by a trial of a SNRI or tricyclic antidepressant. A partial response to the initial 
antidepressant can be followed with augmentation with buspirone, or (if insomnia) 
hydroxyzine.52 Second-line medications for generalized anxiety disorder include 
tricyclic antidepressants, benzodiazepines, and certain anticonvulsants. Finally, 
non-response after adequate trials of second-line antidepressants can be followed 
by trials of other less well studied antidepressants.52
3.4 Medication insurance programs in Quebec  
3.4.1The RAMQ medication insurance 
The Quebec Universal drug insurance plan administered by the Régie de 
l’assurance maladie du Québec (RAMQ) is the only universal plan in Canada that 
is based on a private and public partnership. Since January 1997, it is mandatory 
for all residents of Quebec to have a drug insurance coverage.2 Those that do not 
have access to a collective drug insurance plan through their employer or their 
spouse’s employer are automatically covered by the RAMQ’s public drug insurance 
plan for their medications. Approximately 43% of the Quebec population is covered 
by the RAMQ drug insurance plan,2 including the elderly (>65 years), beneficiaries 
of social assistance, and workers and their families (called adherents) without 
private drug insurance coverage and 57% by a private drug insurance plan. When 
considering individuals less than 65 years, the proportion of subjects covered by 
the RAMQ decreases to 30%, leaving 70% of this sub-population covered by a 
private plan.2
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Coverage through the public drug plan for Quebec residents requires the 
payment of a premium, whether or not they purchase prescription drugs. The 
premium is paid through the Ministère du revenu du Quebec when income tax 
returns are filed. In 2011, the amount varied from 0$ to 563$ per adult which was 
dependent on their family income.53
Those exempted for payment of premiums are holders of a claim slip issued 
by the Ministère de l’emploi et de la solidaritié sociale to those on financial 
assistance which allows free access to prescription drugs and certain medical 
services. Also, persons age 65 or over receiving 94% to 100% of guaranteed 
income supplements (GIS) and children of parents covered by the RAMQ drug 
insurance plan are exempted. This includes all children under 18 year of age and 
full time students without a spouse and who live with their parents.53
The monthly deductible of 16$ is a fixed amount when making the first drug 
purchase during the month. The monthly co-insurance is the percentage of the cost 
of the prescription (32%) subtracting the deductible. The maximum monthly 
contribution is 80.25$ and the maximum annual contribution is 963$. The prices of 
drugs are indicated in the Liste de médicaments reimbursed by the RAMQ which 
are applicable only to those under public drug insurance. Under certain 
circumstances les médicaments d’exceptions which are drugs not included in the 
Liste de médicaments can be reimbursed if a request is made by the prescribing 
physician.53
The prices of drugs under the RAMQ are the same in every pharmacy since 
drug prices are negotiated with suppliers by the federal government. The 
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pharmacist then adds a standardized dispensing fee. A portion of the cost of a 
prescription is payable by the patient which is called the contribution while the 
other portion is paid by the RAMQ directly to the pharmacy.53
3.4.2 Private drug insurance plans in Quebec
Coverage through a private drug plan in Quebec also requires a premium, 
whether or not one goes to purchase prescription drugs. In most cases the 
premium is paid through payroll deductions throughout the year. The premium is 
negotiated between the policy holder and the insurer.  
For the majority of private insurance plans only a portion of the cost of the 
drugs are paid by the insured known as the contribution and the balance is 
reimbursed by the insurer. There are three types of reimbursement methods. 
Certain private plans allow the persons they insure to pay the pharmacy only the 
amount of their contribution, while other plans require them to pay the pharmacy in 
full at the time of purchase and reimburse them afterwards for the difference.54 The 
reimbursement can be done automatically or manually with the individuals having 
to file a claim. Private drug insurance plans are required to reimburse all drugs on 
the list de médicament and the maximum paid per year by an individual is the 
same as in the RAMQ.53
At last, although there are important differences in both plans, the vast 
majority of Canadian studies on the impact of non-optimal drug use have been 
conducted among patients covered by public drug insurance plans. On the other 
hand, research on the usage of prescription drugs among patients covered by 
private drug insurance programs in Canada is almost nonexistent. This is mainly 
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due to the absence of computerized drug databases that can be easily linked to 
other health databases. As described above these two drug plans have many 
differences and may therefore have discrepancies between these two 
subpopulations as to the usage of antidepressants particularly in adherence, 
persistence and the associated costs on the health care system.  
3.5 Adherence to antidepressants 
To date, there is no consensus on the exact definition of adherence to 
medications. As a result, the methods for defining adherence differed across the 
studies, as were cut off values in categorizing an adherent patient. However, 
adherence is generally understood as the extent to which an individual’s behavior 
coincides with medical advice.55,56 This section will provide a review of 
observational studies that have investigated adherence rates to antidepressants.  
 Several studies in the US studies and Canada examined adherence to 
antidepressants.57,58 In a US study of privately insured patients with a diagnosis of 
depression or anxiety, adherence to incident use of selective serotonin reuptake 
inhibitors (SSRIs), one of the most used subclass of antidepressants,45 was 
examined using three different measures of adherence [MPR, length of therapy 
(LOT) and a hybrid measure (MPR/LOT)]. Six month adherence rate was found to 
be approximately 43% (42.9-44.6) for all methods.57 Adherence for new users of 
SSRI’s indicated for depressive disorders were also examined in private employer 
insurance medical claims data. Three different SSRI drugs were compared; 
Fluoxetine, Sertraline and Paroxetine. Six month adherence was defined as 
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receiving at least four antidepressant prescriptions over the six months period was 
highest for Fluoxetine (57%) compared to 48% and 49% for Sertraline and 
Paroxetine respectively.58
Lastly, a study investigating non-adherence to psychotropic medications 
among Canadians of all insurance groups was assessed by the Canadian 
Community Health Survey.59 Non-adherence was defined as a positive answer to 
an interview question asking “on a typical month were there any days where you 
either forgot to take the medicine or took less than you were supposed to?” 
Antidepressants had a 46% (95% CI 43-49) rate of non-adherence.59 The authors 
were not able to exclude recall bias as a possible limitation because of the way the 
outcome was assessed. This survey was also used by Duhoux et al. in assessing 
adequacy of treatment for Canadians suffering from major depressive disorder and 
examining factors associated with this adequacy. Interestingly in this study, having 
medication insurance was not a significant predictor of adequate treatment for 
major depressive disorder.
37
Several studies outside the U.S and Canada studied adherence to 
antidepressants. These studies were not presented in table 2 because of their lack 
of comparability with the Quebec population.  In one study, a retrospective chart 
review was performed on 367 Japanese adult patients diagnosed with major 
depression.60 Adherence to incident use of antidepressants as a class was 
estimated to be 77% using the medication possession ratio (MPR) with 55.6% of 
patients having a MPR>80% which was defined as adherent to therapy.60 Another 
Japanese study conducted an internet based survey among 1151 Japanese 
individuals with major depressive disorders where adherence was measured by 
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asking on a scale from 0 to 5 how often they forget to take their antidepressants. 
The authors found that 33.1% of these patients were classified in the low 
adherence group defined as a score of ≤ 3.61
A retrospective study in Thailand using pharmacy data on newly diagnosed 
major depressive patients in a psychiatric hospital measured adherence using 
MPR (>80% defined as adherent). Only patients aged 15 years or older who 
received at least one prescription of an antidepressant were eligible. Results 
showed that 41% of patients were adherent for those attending the center twice.62
In a European study on patients diagnosed with recurrent depression, 
patients who previously took part in a clinical trial were studied to assess the effect 
of cognitive behavior on relapse prevention. These patients were recruited in 
psychiatric centers in the Netherlands and adherence to antidepressants was 
measured with a medication adherence questionnaire which defined non-
adherence as missing 20% or more of their medication. Non-adherence rates 
ranged between 39.7% and 52.7% over 2 years.
63
In a retrospective database study using the public health service prescription 
in the health region of Lleida, Spain, adherence to 7525 new users of 
antidepressant treatment for all indications with the exception of neuropathic pain 
was measured. Adherence was considered good if the medication was dispensed 
during 80% of the treatment period of 4 months. Twenty two percent of patients 
had good adherence. Also patients with high polypharmarcy were twice as likely to 
present good adherence (31% vs. 15.3%).64
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In summary, in the eight observational studies summarized above, the 
reported adherence rates varied greatly, ranging from 15% to 77%. This wide 
range is likely the results of the different methods of measuring adherence, as well 
as the different patient populations being investigated. Furthermore, the follow-ups 
different greatly between the studies, and thus studies with relatively short follow-
up were more likely to report higher adherence rates than those with longer follow-
up. Table 2 below presents a summary of Canadian and US studies that have 
investigated adherence to antidepressants. 
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Table 2. Summary of Canadian and US observational studies of adherence to antidepressants 
Authors Study design Setting 
Study 
population 
Drugs 
investigated
Definitions Main results Weaknesses
Dehoux et al.
37
n=1563 Cross sectional survey 
Canadian 
community 
health survey 
and well being 
Age 15 or older 
Male 46.3% 
MDD patients 
Antidepressants
Prescription of 
antidepressant and 4 
visits to MD or 12 
visits to 
psychologists 
Adherent 
28% Recall bias 
Cantrell et al.
57
n=22,947 
Retrospective cohort 
U.S 
Database 
private 
Mean age 43 years 
male 36.1% 
SSRI
fluoxetine, 
sertraline, 
citalopram, 
escitalopram, IR 
paroxetine, 
paroxetine CR 
6month 
adherence 
Lot*
MPR 
MPR/Lot 
43% (42.9-44.6) 
Three Metrics not 
statistically different.
Generalizability 
Crown et al.
58
n=2030
Retrospective cohort 
U.S Electric 
pharmacy data 
Insurance claims
mean age 42 years 
male 31%  
Depressed 
population 
fluoxetine, 
sertraline 
paroxetine
6 months  
adherence 
(at least 4 
prescriptions in 6 
months) 
Fluoxetine 57% 
adherent 
Sertraline 48% 
adherent 
Paroxetine 49% 
adherent 
Generalizability 
Bulloch et al.
59
n=6201 
Cross sectional survey
Canadian 
community 
health survey 
and well being 
18-64 years old 
Antipsychotics  
Non adherence 
defined as yes to 
“forgetting or taking 
less medication than 
supposed to in the 
last 12 months:  
45.4% non-adherent 
for antidepressants 
Recall bias 
*MPR: medication possession ratio 
*Lot: Length of therapy  
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Researchers have studied factors associated with adherence to 
antidepressants. Low education has been shown to be a strong predictor of better 
adherence.65 Studies have also shown than being treated by a psychiatrist when 
compared to a general practitioner is associated with better adherence.65 One of 
the most common reasons for poor adherence is their lack of tolerability as side 
effects have been shown to be associated with poor adherence particularly in 
antidepressants.66 Factors that were found to be associated with adherence are 
summarized in the table below in Table 3.   
Table 3. Predictors of adherence to antidepressants
Factors associated with better adherence to antidepressants Odds ratio (95%CI)
Low education65 3.89 (1.11; 13.69) 
Prescription by a psychiatrist65 1.41 (1.25; 1.64) 
Factors associated with lower adherence to antidepressants
Lower age61,65 1.47 (1.05; 2.07) 
side effects
66,67 2.70 (1.21; 6.02) 
Being a worker or student61 2.32 (1.53; 3.51) 
Negative attitude towards antidepressants66 1.64 (1.08; 2.43) 
Use of pain medication65 1.14 (1.04; 1.29) 
Higher daily dosing frequency61 1.61 (1.15; 2.27) 
3.7 Persistence to antidepressants 
As with adherence, there is no consensus on a definition of persistence to 
treatment. However, it generally refers to how long a patient remains on therapy. It 
is often measured with use of prescription refill databases with the assumption that 
patients refill their prescription in order to adhere to treatment. Grace periods are 
usually defined in order to consider the patient persistent even if a given amount of 
time between refills has passed. A small grace period will yield results that 
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demonstrate less persistence while a longer period will yield to evidence of greater 
persistence.68 Selected studies on persistence to antidepressants are summarized 
in table 4. 
Several US and two Quebec studies have examined persistence to 
antidepressants at the population level. A cohort study on adult privately insured 
new users of antidepressants by Bambauer et al. found that 18% of patients did 
not refill their initial prescription in primary care. At six months, 53% of primary care 
patients discontinued their antidepressant prescription. These findings were 
compared to patients treated by a psychiatrist, 13% did not refill their prescription 
initially and 49% at six months.65 Furthermore, Hansen et al studied discontinuation 
rates of antidepressants using medical and prescription claims from a national 
health plan in privately insured adult patients diagnosed with major depression. 
The authors found that 73% discontinued their treatment during the study period of 
7 months.69 In a retrospective cohort study, 71.4% of adult patients with 
depression, posttraumatic stress disorder, or social anxiety disorder who had a 
new prescriptions for brand-name SSRI discontinued their treatment within the first 
six months.70
Vanelli et al. showed using pharmacy records of 1157 pharmacies through 
the US that 38.8% of incident users and 18.8% of prevalent users of 
antidepressants discontinued treatment at 30 days.  Discontinuation was defined 
with a 30day grace period.  At six months, 74.9% of first time users discontinued 
their therapy. As for the prevalent users 48.3% discontinued their therapy within six 
months.71
P a g e  | 23 
In the study by Wu et al. on elderly patients with major depressive disorders, 
the rate of discontinuation defined as no refills within a period of 45 days was 
measured. Six-month discontinuation rates for new users of escitalopram 
compared to other SSRI or SNRI therapies were 60.8% and 65.9% respectively.72
In another retrospective study using a US insurance claims database, the authors 
found similar results using a 60 day grace period demonstrating a better 
persistence with escitalopram than with other SSRI therapy at two months; (66.1% 
vs 61.9% p<0.01) and at six months (47% vs. 41% p<0.01).73 Furthermore, another 
study using claims data from an administrative database on new adult users of 
antidepressants found that sertraline had a better rate of renewals compared to 
paroxetine (54.7% compared to 51.0%) respectively.74 The use of paroxetine was 
also associated with a lower persistence rate compared to citalopram and 
sertraline.70
Bull et al. studied early discontinuation among 401 depressed patients who 
initiated an SSRI treatment through telephone interview. The authors found that 
20% of patients discontinued their treatment after three months. Reasons given for 
ending treatment was side effects (36%) , feeling better (24%), insufficient results 
(20%) and others (20%).75 Olfson et al. found using data from the Medical 
Expenditure Panel survey that 42.4% of depressed adults who initiated an 
antidepressant discontinued treatments 30 days after their initial prescription. 
Furthermore, only 27.6% continued their treatment for more than 90 days.76
Interestingly, this survey did account for discontinuation of treatment rates between 
the private prescription insurance group and the non-prescription coverage group; 
however they were not significantly different. Moreover, private versus public 
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health insurance groups were also compared and only crude rates were 
significantly different however not after adjustment for baseline characteristics OR: 
(0.70 95% CI 0.47-1.04).  
As for Quebec studies, Tournier et al studied an elderly population who 
initiated an antidepressant treatment in 2000 and were followed for 12 months. 
Using the RAMQ database, non-persistence was defined as treatment duration of 
less than 180 days and results showed that 55.6% of antidepressant treatments 
were non persistent.77
Lastly, in a publically insured Quebec population using the RAMQ 
prescription database, persistence to antidepressants was assessed for adults 18 
years and older including patients over 65 years old using a treatment gap of 30 
days. Persistence among incident users was found to be 38.5% at six months and 
28.4% at one year.21
Several studies outside the United States and Canada also examined 
persistence to antidepressants. These studies were not presented in table 4 
because of their lack of comparability with the Quebec population.  The medical 
records of 367 outpatients’ with a major depressive disorder in Japan who were on 
an antidepressant were examined. Persistence at 1 month, 3 month and 6 month 
was 72.8%, 54.0% and 44.3%, respectively. Interestingly 63.1% of these patients 
discontinued their treatment without consulting their physician.60
A Danish study using the National Health Insurance Registry found that 
25.2% of patient discontinued their treatment in the second half-year following their 
initial prescription. Van Geffen et al found that 23.7% of adult first time users of 
antidepressants in the Netherlands refilled their prescription only one time.78
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Another study done in Belgium found that 53% of patients remained on treatment 
when looking at persistence at six months. The median time on treatment was 22 
weeks and 24% of patients did not inform the physician when ending their 
treatment.79
In summary, this section summarized thirteen observational studies that 
have investigated persistence rates to antidepressants. These rates ranged from 
24%% to 75%, demonstrating great heterogeneity between studies. As indicated 
above, such differences are likely due to different methods of measuring 
persistence as well as different patient populations being studied. Furthermore, as 
with adherence, study follow-up is likely to have influenced the reported rates, with 
the longest follow-up periods associated with lower persistence rates. Table 4 
below presents a summary of US and Canadian observational studies that have 
investigated persistence to antidepressants. 
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Table 4. Summary of Canadian and US observational studies of persistence to antidepressants
Authors Study design Setting 
Study 
population 
Drugs 
investigated 
Definitions Main results Weaknesses 
Wu et al.
72 Retrospective cohort 
n=38,775 
U.S 
Database 
MDD 
Diagnosis 
Escitalopram 
(n=10,465) 
SSRI/SNRIs 
(n=28,310) 
Age > 65 years 
Male 34% 
Escitalopram 
or other 
(SSRI/SNRI) 
Non-persistence 
45 days without 
refill 
HR 0.96 (95% CI: 0.94, 0.99) 
HR 0.91 (95% CI: 0.87, 0.94) 
Possible selection 
bias 
Tournier et 
al.
77
Retrospective cohort
n= 12,825
Canada 
Quebec 
Database 
RAMQ 
Age >66 
Male/female 
Trazodone 
Nefazodone 
Fluoxetine 
Fluvoxamine 
Sertraline 
Venlafaxine 
Citalopram 
Paroxetine
Treatment non-
persistence 
(duration of less 
than 180 days) 
Cost persistent 
ratio (CPR)
Others: 
64.6 (95% CI: 62.7–66.5) 
SNaRI: 
53.3 (95% CI: 51.1–55.5) 
SSRI: 
53.1 (95% CI: 52.1–54.2) 
CPR: newer drugs more 
favorable
Information on cost 
and indication 
needed 
Hansen et al.
80 Retrospective cohort
n=4545
US 
prescription 
claims 
database 
Privately-insured 
Male 35% 
Mean age 39 yrs 
Any 
antidepressant 
prescription 
30 day grace 
period 
7-month follow up 
73% discontinued 
Not all drugs 
captured if cash 
purchases 
Vanelli et al.
71 Retrospective cohort
n=211,565
US 
computerize 
pharmacy 
records 
New and 
prevalent users 
of 
antidepressants 
Male 28% 
Venlafaxine 
Paroxetine 
Sertraline 
Fluoxetine 
Escitalopram 
citalopram 
30 day grace 
period 
180-day follow up 
38.8% discontinued in new-
user group 
18.8% discontinued in 
prevalent group 
Missing diagnostic 
information, 
possible 
misclassification 
Esposito et 
al.
73
Retrospective cohort
n=43921
US 
insurance 
claims 
database 
New users of 
antidepressants 
Escitalopram vs 
other SSRI 
generics 
At least 2 
prescriptions 
within 6months 
Escitalopram 47.1% 
continued treatment at 
6months  vs 41.0% for SSRI 
Generalizability, 
indication not 
validated 
P a g e  | 27 
RAMQ 
Conseil du 
médicament
21
Retrospective cohort
n=364,921
Canada 
Quebec 
Database 
RAMQ 
Quebec publicly-
insured adults 
Any 
antidepressant 
prescription 
30-day grace 
period 
1 year follow up 
38.5% persistent at 6 months 
24.8% at 1 year 
Limited to publically 
insured 
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Researchers have studied factors associated with persistence to 
antidepressants. Studies have shown than being treated by a psychiatrist when 
compared to a general practitioner was associated with better persistence.65
Moreover, being on psychotherapy as well was also associated with better 
persistence.76 However, one of the most common reasons for early discontinuation 
is their lack of tolerability as side effects have been associated with early 
discontinuation particularly in antidepressants.45,75 This has been shown to be 
more common in the TCA class.45,69  Thus, discussing these side effects with 
patients is important as it has been associated with better persistence.81  Factors 
that were found to be associated with persistence are summarized in the table 
below.   
Table 5. Predictors of persistence to antidepressants
Factors associated with persistence to antidepressants Odds Ratio (95% CI)
Having a psychiatrist as initial prescriber65,82 1.41 (1.25; 1.64) 
Being treated with more than one professional65,83 1.20 (1.08; 1.33) 
Old age84,85 1.35 (1.14; 1.61) 
Being on psychotherapy76 1.82 (1.22; 2.71) 
Discussing side effects before starting treatment with physicians75 2.04 (1.05; 4.00) 
Being on high polypharmacy64 1.70 (1.60; 1.87) 
Factors associated with non-persistence to antidepressants
Taking a TCA86 2.94 (2.42; 3.58) 
The experience of side effects75 3.20 (2.20; 4.97) 
Low income76 1.56 (1.01; 2.43) 
Level of education (less than 12 years) 76,86 1.89 (1.27; 2.86) 
Being told by the physician to take the treatment for less than six 
months75
3.12 (1.21; 8.07) 
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3.8 Drug insurance, costs and use of antidepressants  
To our knowledge no study has compared antidepressant cost and generic 
use in private and public drug insurance settings. However, to date, only a few 
studies have examined antidepressant costs and how their use varies according to 
different medication insurance coverage’s.  
The three tier formulary in the US resulted in labeling certain brand 
medication non-preferred and required higher copayments for those medications. 
The authors suggest that this has impacted utilization of psychotropic medication 
particularly in antidepressant subclasses.87
In commercially insured patients in the US, higher cost sharing was 
associated with lower likelihood of adherence to second generation antipsychotics. 
Higher cost sharing was also associated with a shorter time to discontinuation as 
well (HR: 1.028 (1.006-1.051).88
Finally, a Canadian study on British Colombia seniors compared 
antidepressant initiation and discontinuation before and after the 2002 introduction 
of copayments and 2003 introduction of income based deductibles for prescription 
drugs.70 Discontinuation was defined as failing to refill a prescription within 90 days 
of exhausting available supply. The authors found a considerable drop in 
antidepressant initiation following the new implementations; however 
discontinuation rates were not affected.  
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3.9 Conclusion 
Antidepressants are widely prescribed in Canada and particularly in 
Quebec. Despite treatment guidelines stressing the importance of maintaining 
adequate adherence without early discontinuation to achieve clinical benefit, there 
are many studies reporting suboptimal usage of antidepressants in private and 
public health care settings. Comparisons of these health insurance settings on 
actual usage of antidepressants are limited to different population settings and 
survey data susceptible to recall bias. In Quebec, studies on the usage of 
antidepressants have been primarily examined in publically insured individuals who 
only represent 43% of the population.21,77 Thus we do not know if this usage is in 
fact comparable to those in privately insured individuals. At last, no studies to date 
have examined the differences present in the usage, costs and generic versus 
brand name utilization of antidepressants within Quebec’s unique public and 
private medication insurance programs. We have therefore studied whether the 
type of drug insurance impacted antidepressant adherence, persistence and costs 
within Quebec’s public and private medication insurance programs.  
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Chapter 4: Methodology 
4.1 Sources of data 
This study used information from three sources: Régie de l’assurance 
maladie du Québec (RAMQ), Maintenance et Exploitation des Données pour 
l`Étude de la Clientèle Hospitalière (Med-Écho) and reMed. The RAMQ 
administrative database provides medical coverage to all Quebec residents and 
drug coverage to approximately 43% of the population.89This includes the elderly 
(>65 years), beneficiaries of social assistance, and workers and their families 
(called adherents) who do not have access to a private drug insurance plan from 
their workplace. The RAMQ database includes three types of files. The Beneficiary 
file gives information on patients’ characteristics, such as age, sex, area of 
residence, social aid status and periods of coverage for the medication insurance. 
The Medical Services file contains all the information relative to medical services 
received e.g. the type, date, and location of medical service (outpatient clinic, 
emergency department (ED), hospitalization), diagnostic codes, as well as the 
specialty of the treating physician. The Prescription Drugs file contains data on 
prescribed medications dispensed in community pharmacies and includes notably 
the name of the medication, dosage, amount of medication given to the patient, the 
dispensing date, the type of prescription (new or refill), the number of refills allowed 
with a new prescription, the prescription duration, and the specialty of the 
prescribing physician. The Med-Echo database contains information on all acute 
care hospitalizations occurring in the province, the date of admission and length of 
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stay as well as primary and secondary diagnoses. These two administrative 
databases are routinely used90,91 and validated for epidemiological research.92,93
 reMed is a computerized on-going registry which stores data related to 
prescribed medications for residents in Quebec who are <65 years old and 
beneficiaries of a private or group insurance drug plan provided by an employer. 
Patients were recruited in hospitals, medical clinics and community pharmacies. 
Recruiting patients would be done by approaching potential candidates with a brief 
explanation of the use and contents of the reMed database and a signed consent 
form if eligible. In addition, reimbursement of medications had to be done 
automatically as a requirement to be included in reMed. This registry is based upon 
the data that are purchased from the community pharmacies’ computer services 
providers, who manage the data transmission that is required for drug 
reimbursement by the private insurance companies. Drug data is be updated every 
two weeks. The registry contains information on patient characteristics such as 
age, sex, smoking status, body mass index and periods of coverage for medication 
insurance. It also gives information on prescribed drugs such as the name of the 
medication, dosage, dispensing date, duration of treatments, number of refills 
allowed as well as all associated costs. 
The Med-Écho database provides information on acute care hospital 
admissions including data on the patient unique identifier (encrypted), the 
discharge diagnoses, and the duration of the hospitalization for all residents of 
Quebec. 
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4.2 Ethical considerations  
The study was granted approval by the scientific and ethics committee of 
Hôpital du Sacré-Coeur de Montréal (HSCM) and la Commission de l’accès à 
l’information (CAI) which is responsible for administering the Act respecting access 
to documents held by public and private bodies and the protection of personal 
information. 
4.3 Study design and study population 
A retrospective matched cohort study was conducted through the linkage of 
the three databases previously described. To achieve the study objectives, we first 
selected reMed patients who received at least one prescription of an 
antidepressant agent in monotherapy from the following subclasses: selective 
serotonin reuptake inhibitors (SSRI), selective norepinephrine reuptake inhibitors 
(SNRI), tricyclic antidepressants (TCA) and other second-generation drugs 
(Bubropion, Nefazodone, Mirtazapine, Trazodone, Moclobemide, Phenelzine and 
Tranylcypromine) from March 22nd 2008 until May 15th 2009. The index date was 
defined as the calendar date of the first prescription for an antidepressant filled 
after the date of recruitment in reMed. Patients had to be aged between 18-64 
years at the index date. In the RAMQ cohort we selected patients who do not 
receive social assistance (the so called adherents), aged 18-64 years old that were 
prescribed at least one antidepressant agent in monotherapy between December 
1st 2007 and September 30th 2009. Patients from reMed were matched to those of 
RAMQ (up to 10 RAMQ patients for each reMed patient) on age group (20-34, 35-
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49 and 50-64), sex, CLSC territory (region of local community service center) and 
index date. Matching for index date was done by choosing for each reMed patient, 
the RAMQ patients with the closest prescriptions of an antidepressant dispensed in 
a period ranging between 2 months prior until 4 months after the index date of the 
reMed patient.   
All patients were required to have at least 3 months of follow-up, and were 
followed until the first of the following events: 2 years of follow-up, 65th birthday, or 
termination of coverage by a private drug insurer for reMed patients or public drug 
insurer for RAMQ patients. Finally, in order to properly measure potential 
confounders we also obtained information on patients one year prior to index date.
4.4 Outcome variables 
4.4.1 Physician adherence to antidepressants 
We estimated physician adherence to the guidelines. The physician 
adherence was calculated by dividing the total days’ supply prescribed by the total 
duration of the study. 
Physicians adherence =  
Total days’ supply prescribed/ total days of study duration 
Total days’ supply prescribed was obtained by summing the duration of all 
prescriptions and the duration of all allowed refills of antidepressants recorded from 
all the physicians who prescribed antidepressant to a patient during the 12-month 
follow up period. The numerator was truncated to 365 days to exclude excess 
medication prescription.  
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4.4.2 Patient adherence to antidepressants 
Adherence to a drug regimen is the extent to which a patient actual history 
of drug administration corresponds to the agreed upon prescribed regimen. 94
Initially, a measure of refill adherence frequently used in studies was used. 
This adherence measure, referred as the proportion of days covered (PDC), is 
defined as the ratio of the total days’ supply dispensed during the follow up over 
the number of days of follow up.94
PDC= total days’ supply dispensed/ total days of study participation 
Although the PDC adherence measure provides an accurate reflection of the 
use of medication throughout the duration of the study it may not accurately reflect 
patient adherence to their prescribed medication. In the presence of differing 
prescribing patterns, the PDC may fail to provide information about whether the 
patient is using the medication as prescribed. 
The PPDC is an improved measure of adherence and is defined as total 
days’ supply dispensed/ total days’ supply prescribed. By using a denominator that 
corresponds to the number of days of follow up, the PDC assumes that the 
medication was prescribed for chronic daily use. The PDC reflects the behaviour of 
both the patient and the prescribing physician and consequently the usage of 
medications, while the PPDC tends to measure more specifically the behaviour of 
the patient as it measures patients adherence to the therapy that was actually 
prescribed, and not to the therapy that should have been prescribed according to 
clinical guidelines.
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Both the numerator and denominator of the PPDC and PDC were truncated 
to 365 days to exclude excess medication possession and medication prescription, 
respectively. 
4.4.3 Persistence to antidepressants 
Persistence to treatment refers to how long a patient remains on therapy. 
Using our prescription refill databases with the assumption that patients refill their 
prescription in order to adhere to treatment, persistence with antidepressants was 
calculated at one year for patients being followed for at least 90 days. Patients 
were considered persistent if they continuously refilled their antidepressant 
prescription with gaps of 60 days or less (grace period) between the end of a 
prescription and the date of the next refill. Sensitivity analyses were conducted by 
varying the grace period using 45 and 90 days. Analysis of persistence for the 
subclasses was also calculated.  
4.4.4 Cost 
Cost of antidepressant medications was measured using the average cost 
per patient per month in CAN$. We took into consideration both the cost of 
medication and the honorarium of the pharmacist which might vary between public 
and private insurers. We also examined if there were cost differences between 
insurance groups amongst classes of antidepressants as well as the individual 
drugs. The product specific analysis was based on 30 days prescriptions and 
stratified by sub-class and brand name verse generic use.  
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4.4.5 Generic versus brand name antidepressants 
Differences in generics versus branded medications prescribed were 
measured by comparing the proportion of generic antidepressants in publicly and 
privately insured patients. 
4.5 Potential confounders 
Demographic variables measured at index date were gender, age (20-34, 
35-49 or 50-64), year at cohort entry (2007-2008 or 2009). Potential confounders 
measured in the year before the cohort entry included comorbidities (i.e. 
hypertension, dyslipidemia, other cardiovascular diseases, diabetes, 
gastrointestinal diseases, respiratory diseases and inflammation) – which were 
measured using filled prescriptions of medications indicated to treat the diseases 
(Appendix 3) -, all cause hospital visits, all cause emergency room visits, and all 
cause outpatient visits. We also assessed whether the patients were incident or 
prevalent users of antidepressants. Incident users were defined as not having a 
prescription of an antidepressant in the year prior to cohort entry. Prevalent users 
were defined as having filled a prescription of an antidepressant in the year prior to 
cohort entry. Finally, we considered the indication of the prescription (i.e. 
depression, anxiety, adjustment disorders and other diagnoses) as a potential 
confounder. Indication was evaluated based on the International Classification of 
Diseases 9 and 10 diagnoses codes in the Med Écho database. The 
antidepressants subclasses were not entered in the models for adherence, 
persistence and cost because this variable might be in the casual pathway 
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between type of drug insurance and the outcomes (adherence, persistence or 
cost).  
4.6 Exposure 
The exposure of interest was the type of drug insurance plan being either 
public or private. The RAMQ cohort represents the public drug insurance plan 
whereas the reMed cohort represents individuals enrolled in private drug insurance 
plan. 
4.7 Statistical analyses 
4.7.1 Descriptive analysis 
The analysis started with a description of the cohort. We measured the 
proportions of individuals in each exposure group for various patient 
characteristics.  
4.7.2 Adherence 
Mean PPDC and PDC and 95% confidence intervals for antidepressant 
agents were calculated for both the entire class and subclasses among patients 
with private and public drug insurance.  Linear regression analysis was used to 
compare PPDC as well as PDC between privately and publically insured patients 
for all users and new users of antidepressants. All relevant potential confounders 
were included in the initial full model. A backward selection strategy was used to 
select the final models.94 Predictors were defined as a change of at least 10% in 
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the mean difference associated with the type of insurance when removed from the 
model.  Those found to be a significant predictor of the outcome (p-value 0.05) 
were kept in the final model.94
4.7.2.1 Subgroup analyses 
Linear regression analysis for adherence was performed in SSRI and SNRI 
subclasses of antidepressants separately. Furthermore, incident users of 
antidepressants were examined to see if differences were present in these SSRI 
and SNRI subclasses as well.  
4.7.3 Persistence  
The cumulative persistence rate was analyzed for incident users of 
antidepressants for the entire class using a Kaplan-Meier curve. Log rank test was 
used to evaluate differences between private and public groups. A Cox regression 
model was used to estimate the hazard ratio of non-persistence for all incident 
users of the entire class of antidepressants. The model was adjusted for the 
potential confounders outlined above using a backward selection strategy.   
4.7.4 Costs  
After testing for normality, linear regression analyses were used to compare 
the cost of antidepressant medications between patients with public and private 
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drug insurance. All relevant potential confounders were included in the initial full 
model. Backward selection strategy was used to select the final model.94T-tests 
were used to see if differences in costs were significant for prescriptions between 
the two insurance groups for the product specific analysis. This analysis was done 
for 30-day prescriptions only to ensure comparability among cost and duration of 
prescriptions. 
4.7.5 Generics versus branded medications 
Differences in generics versus branded medications prescriptions were 
measured by looking at the proportion of generic antidepressants in privately and 
publicly insured patients. Chi-squared tests were used to see if differences are 
significant. All analyses were performed using SAS software, version 9.2 (SAS 
Institute inc., Cary, NC USA). 
4.7.6 Power calculations 
We are planning a study with 194 privately insured patients and 1923 
publically insured patients.  With an alpha of 0.05 and a mean difference of 
adherence of 5% we will be able to reject the null hypothesis that the population 
means of the experimental and control groups are equal with probability (power) 
100%.  
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Chapter 5: Manuscript 
The results of this thesis are presented in the following manuscript: 
The manuscript was submitted to the Canadian Journal of Psychiatry. The principal 
author confirms his original contribution to the cohort assemblies, statistical 
analyses and interpretation of the results, as well as in the writing of the research 
article. 
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5.1 Abstract  
Background: The impact of the type of drug insurance plan on adherence and 
persistence to antidepressants is not well known. The aim of the present study was 
to compare adherence, persistence and cost of antidepressants in Quebec patients 
who are covered by private and public drug insurance.  
Methods: A matched cohort study was conducted using prescription claims 
databases: the reMed and RAMQ databases for Quebec residents with private and 
public drug insurance, respectively. Patients were aged 18 to 64 years and filled at 
least one prescription for an antidepressant in monotherapy between December 
2007 and September 2009 (194 privately and 1923 publicly insured patients). 
Adherence over one year was estimated using the proportion of prescribed days 
covered (PPDC). The difference in mean PPDC between patients with private and 
public drug insurance was estimated with a linear regression model. Persistence 
was compared between the groups with a Cox regression model while the monthly 
cost of antidepressants (CAD$) was compared between the two groups using 
linear regression. 
Results: The PPDC was 86.4% (95% CI: 83.3-89.5) in patients with private and 
81.3% (95%CI: 80.1-82.5) in patients with public drug insurance and the adjusted 
mean difference was 6.7% (95% CI: 3.0-10.4). Persistence was 49.5% in patients 
with private and 18.9% in patients with public drug insurance at one year 
(p<0.001); the adjusted hazard ratio was 0.48 (95%CI: 0.30-0.76). Patients 
privately insured paid $14.94 CAD (95% CI: 12.30; 17.58) more per month on 
average for their antidepressants.
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Conclusion: Better adherence and persistence and higher costs were observed in 
privately-insured patients. Cost difference might be due to different pharmacy 
payment requirements and the pharmacists’ honorary restrictions under the public 
plan. 
Keywords: antidepressant agents, medication adherence, drug costs, 
retrospective studies, insurance health PDC, PPDC 
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5.2 Background 
According to national estimates, about 6 % of Canadians and 10% of 
Americans are treated with antidepressants.(1;2) Although these drugs are 
predominantly used for the treatment of depression, they are also prescribed for 
numerous other indications such as anxiety, fibromyalgia, and migraines.(3;4) 
These indications incur a heavy economic burden;(5) it is estimated that 
depression alone represents over 2.6 billion dollars in health care costs and loss of 
productivity in Canada and 83 billion in the US annually.(6;7) It is also well 
documented that increasing adherence and persistence to antidepressant 
medication leads to improved clinical outcomes and reduces the likelihood of 
relapse, thus reducing the associated economic burden.(8) However, despite 
consensus regarding the importance of maintaining adequate dose and adherence 
for all phases of antidepressant treatment, there is increasing evidence that 
patients do not adhere to their treatment regimen.(9-11) 
Studies have investigated adherence and persistence rates with 
antidepressants (4;9-14), with adherence ranging between 42% and 51% at six 
months among privately-insured Americans and Canadians (9)  (11;12), and 
persistence being 28.4% at one year among publicly-insured patients from 
Quebec, Canada(4) . Adherence is generally defined as the extent to which a 
patient takes medications as prescribed,(15) while persistence is defined as the act 
of continuing treatment for the prescribed duration.(16)  
Even if factors known to have an impact on patient’s adherence and 
persistence such as premiums, deductibles, co-payments, formulary restrictions, 
and reimbursement policies are likely to differ between private and public drug 
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insurance plans,(17) we found only one study performed among Latino Americans 
that compared the use of antidepressants between patients publicly and privately 
insured. This study reported higher discontinuation rates of antidepressants among 
publicly compared to privately-insured patients.(18)  
Therefore, using prescription claims databases from Quebec (Canada), we 
conducted a matched cohort study to evaluate the differences in adherence and 
persistence to antidepressants between patients publicly and privately insured for 
their medications. We also compared the costs of antidepressants and use of 
generics versus branded antidepressants between these two sub-populations. 
P a g e  | 47 
5.3 Methods 
Under the Universal drug insurance plan administered by the Régie de 
l’assurance maladie du Québec (RAMQ), it is mandatory for all residents of 
Quebec to have drug insurance coverage.(19) Those that do not have access to a 
private drug insurance plan through their employer or their spouse’s employer are 
automatically covered by the RAMQ’s public drug insurance plan (the same plan 
for all publicly insured residents). Approximately 43% of the Quebec population is 
covered by the RAMQ’s public drug insurance plan(19) including the elderly (≥ 65 
years), beneficiaries of social assistance, and workers and their families not 
admissible to a private drug plan, and the remaining are covered by private plans 
that vary from one workplace to the other. When considering individuals less than 
65 years of age, the proportion of subjects covered by the RAMQ’s public drug 
insurance plan decreases to 30%.
5.3.1 Study design 
A database matched cohort study was conducted to compare workers with private 
and public drug insurance. Patients publicly insured were restricted to workers not 
admissible to a private drug plan (excluding elderly and patients on social welfare) 
in order to minimize socio-economic differences between patients with public and 
private drug insurance. We first selected privately-insured patients aged 18-64 
years who received at least one prescription of an antidepressant in monotherapy 
(selective serotonin reuptake inhibitors (SSRI), selective norepinephrine reuptake 
inhibitors (SNRI), tricyclic antidepressants (TCA) and other second-generation 
antidepressants (Bubropion, Nefazodone, Mirtazapine, Trazodone, Moclobemide, 
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Phenelzine and Tranylcypromine) from March 15th 2008 to May 15th 2009 from 
the reMed database. Cohort entry was defined as the calendar date of the first 
prescription for an antidepressant filled on or after March 15th, 2008. reMed is a 
computerized registry which stores data related to prescribed medications (name, 
date of dispensing, quantity dispensed, duration of the prescription, dosage form, 
dose, number of allowed refills, etc.) for a sample of Québec residents who are <65 
years old and covered by a private drug insurance plan with electronically 
processed reimbursement and recruited in community pharmacies, medical clinics, 
or blood sampling centers. Drug data are purchased from the community 
pharmacies’ computer services providers, who manage the data transmission that 
is required for drug reimbursement by the private insurance companies, and stored 
prospectively in reMed. reMed contains also information on patient characteristics 
such as age, sex, smoking status, and body mass index, collected at recruitment.  
For each privately insured patient, we selected up to 10 users of antidepressants 
among patients covered by the public drug insurance and recorded in the RAMQ 
database, restricting inclusion to the workers not admissible to a private drug plan. 
The RAMQ Prescription Drugs file contains data on prescribed medications 
dispensed in community pharmacies and includes the same drug information as 
the one included in reMed. Publicly insured patients were aged 18-64 years old 
and filled at least one prescription for an antidepressant in monotherapy between 
December 1st 2007 and September 30th 2009, and were matched to privately 
insured patients on age group, sex, region of local community service centre (in 
order to further minimize socio-economic differences), and date of cohort entry 
(within 4 months prior and 6 months after the date of cohort entry of the matched 
privately insured patient).   
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All patients were required to be registered in reMed or RAMQ database for at least 
one year prior and 3 months after cohort entry, and were followed until the first of 
the following events: 1 year of follow-up, 65th birthday, the start of a poly-therapy, 
a switch between public and private drug plans, or the end of the study period 
(April 31st 2010). For all selected patients, we also obtain data on medical services 
(date, location (outpatient clinic, emergency department (ED), hospitalization), 
diagnosis,  specialty of the treating physician, etc.) from the RAMQ database, and 
on hospitalizations from the Maintenance et Exploitation des Données pour l`Étude 
de la Clientèle Hospitalière (Med-Echo) database (20) for the year preceding and 
the year following cohort entry. These administrative databases are often used for 
research(21;22) and the information related to medications has been proven 
valid.(23)
5.3.2 Drug plans  
For the public drug insurance plan, which is the same for all insures, the 
premium is collected annually via income taxes and the amount varies between 0 
and $563 per year according to family income. The deductible is fixed at $16 per 
month, the co-payment is fixed at 32% of the cost of the medications and the 
maximal monthly contribution is $80.25 ($963 per year).(24) Private plans vary 
from one workplace to the other with premiums negotiated with the insurer and 
usually taken in the form of payroll deductions throughout the year. The deductible 
is usually applicable to a one year period representing the first portion of a person's 
drug costs, while the co-payment varies between 0 and 32%, depending on the 
plan. The private plans should cover at least all medications covered by the public 
plan and the maximal contribution is set at $963 per year for all plans. 
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Reimbursement with private plans can be made at the time of purchase or differed, 
while patients on the public plan are always reimbursed at the time of purchase. 
5.3.3 Outcome variables 
Patient adherence to antidepressants was measured in the year following 
cohort entry using the Proportion of Prescribed Days Covered (PPDC) which is 
defined as the total days supply dispensed over the total days supply prescribed 
during the follow up period.(25;26) The total days supply dispensed was calculated 
by summing the duration of all prescriptions of antidepressants (new and refills) 
dispensed over the follow-up period. The total days supply prescribed is obtained 
by summing the duration of all new prescriptions and the duration of all allowed 
refills of antidepressants prescribed from any physician during the follow-up period. 
The duration of allowed refills is summed whether or not the patient went to the 
pharmacy to get the refills.  
The PPDC is an improved version of an adherence measure commonly 
used with prescription claims data known as the Proportion of Days Covered 
(PDC), which we also measured in the present study for comparison purposes. 
The PDC is defined as the total days supply dispensed during the follow-up over 
the number of days of follow up. (27) By using a denominator that corresponds to 
the number of days of follow up, the PDC assumes that the medication was 
prescribed for daily use during the entire follow-up. The PDC reflects the behaviour 
of both the patient and the prescribing physician, while the PPDC tends to measure 
more specifically the behaviour of the patient as it measures patient adherence to 
the therapy that was actually prescribed.  
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Patients were considered persistent if they continuously refilled their 
antidepressant prescription with gaps of 60 days or less (grace period) between 
the end of a prescription and the date of the next refill. Sensitivity analyses were 
conducted by varying the grace period using 45 and 90 days.     
Cost of antidepressants was retrieved from the RAMQ and reMed 
databases, expressed in CAD$, and took into consideration both the cost of the 
medication and the honorarium of the pharmacist. 
5.3.4 Potential confounders 
Demographic variables measured at cohort entry were gender, age (20-34, 35-49 
or 50-64 years), and calendar year (2007-2008 or 2009). Variables measured in 
the year before cohort entry included co-morbidities (hypertension, dyslipidemia, 
other cardiovascular diseases, diabetes, gastrointestinal diseases, respiratory 
diseases and inflammation) – which were measured with filled prescriptions of 
medications indicated to treat the diseases –, all cause hospitalisations, all cause 
emergency room visits, and all cause ambulatory medical visits. We also assessed 
whether the patients were incident or prevalent users of antidepressants at cohort 
entry. Incident users were defined as not having a prescription of an 
antidepressant recorded in reMed or RAMQ databases in the year prior to cohort 
entry. Finally, we considered the indication for the antidepressant (i.e. depression, 
anxiety, adjustment disorders and other diagnoses) evaluated based on the 
International Classification of Diseases 9 and 10 diagnosis codes recorded in the 
RAMQ or Med-Echo databases in the year prior to cohort entry.  
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5.3.5 Statistical analyses  
Descriptive statistics were used to summarize patient characteristics. PPDC 
and PDC for antidepressants as a class were calculated among patients with 
private and public drug insurance over a period of at least 3 months and up to one 
year. The proportion of patients with a PPDC> 80% and with a PDC >80% 
(considered as adherent)(28) were also calculated. Linear regression models were 
used to compare the mean PPDC and PDC between privately and publicly-insured 
patients. Final models were identified by using a backward selection procedure, 
starting with a model that included all of the aforementioned potential 
confounders.(25) The final model was obtained when no independent variable can 
be removed from the model without modifying the beta parameter associated with 
the type of insurance by 10% or more.(25) These analyses were performed among 
all patients and also among incident users only. 
Kaplan-Meier curves were used to estimate treatment persistence to 
antidepressants as a class among incident users. A Log rank test was used to 
evaluate differences between private and public groups and a Cox proportional 
hazard model with a backward selection procedure was used to estimate the 
adjusted hazard ratio of non persistence associated with the type of drug insurance 
plan.  
We estimated the average monthly cost of antidepressants as a class and 
for sub-classes among patients privately and publicly insured. These average costs 
were compared between the groups using t-tests. It is worth noting that we did not 
take into account adherence when calculating monthly cost. In addition, a linear 
regression model was used to estimate the adjusted mean difference in the 
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monthly cost of antidepressants between patients with public and private drug 
insurance. A backward selection strategy was used to select the final model.(25) 
We also compared the cost of a 30-day prescription for each antidepressant 
product between the two insurance groups using t-tests. This analysis was done 
for 30-day prescriptions only to ensure comparability among cost and duration of 
prescriptions. Finally, we compared the proportion of generic antidepressants 
between privately and publicly-insured patients using Chi-squared tests. All 
analyses were performed using SAS software, version 9.2 (SAS Institute Inc., 
Cary, NC USA). 
Descriptive statistics were used to summarize patient characteristics. Crude 
PPDC and PDC for antidepressants as a class were calculated among patients
with private and public drug insurance over a period of at least 3 months and up to 
one year. The proportion of patients with a PPDC> 80% and with a PDC >80% 
(considered as adherent)28 were also calculated. Linear regression models were 
used to compare the mean PPDC and PDC between privately and publicly-insured 
patients. Final models were identified by using a backward selection procedure, 
starting with a model that included all of the aforementioned potential 
confounders.25 The final model was obtained when no independent variable can be 
removed from the model without modifying the beta parameter associated with the 
type of insurance by 10% or more.25 These analyses were performed among all 
patients and also among incident users only. 
Kaplan-Meier curves were used to estimate treatment persistence to 
antidepressants as a class among incident users. A Log rank test was used to 
evaluate differences between private and public groups and a Cox proportional 
hazard model with a backward selection procedure were used to estimate the 
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adjusted hazard ratio of non persistence associated with the type of drug insurance 
plan.  
We estimated the average monthly cost of antidepressants as a class and 
for sub-classes among patients privately and publicly insured. These average costs 
were compared between the groups using t-tests. It is worth noting that we did not 
take into account adherence when calculating monthly cost. In addition, a linear 
regression model was used to estimate the adjusted mean difference in the 
monthly cost of antidepressants between patients with public and private drug 
insurance. A backward selection strategy was used to select the final model.25 We 
also compared the cost of a 30-day prescription for each antidepressant product 
between the two insurance groups using t-tests. This analysis was done for 30-day 
prescriptions only to ensure comparability among cost and duration of 
prescriptions. Finally, we compared the proportion of generic antidepressants 
between privately and publicly-insured patients using Chi-squared tests. All 
analyses were performed using SAS software, version 9.2 (SAS Institute Inc., 
Cary, NC USA).  
5.3.6 Ethical considerations 
The study was granted approval by the scientific and ethics committee of 
Hôpital du Sacré-Coeur de Montréal and la Commission de l’accès à l’information 
which is responsible for administering the Act respecting access to documents held 
by public and private bodies and the protection of personal information. 
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5.4 Results 
A total of 194 patients met the study inclusion criteria for the privately-
insured group and 1,923 patients for those publicly insured. As presented in Table 
6, we observed that 46% of the patients were aged between 50 and 64 years old 
and about 23% were males. The groups were comparable for all variables, except 
for the proportion of patients who were incident users of antidepressants and the 
proportion of patients who filled a prescription for inflammation that were higher in 
the privately-insured group. However, the duration of follow-up was higher in the 
publicly-insured group (p<0.001).  
Crude adherence rates are outlined in Table 7. Patients privately insured 
were significantly more likely to be adherent to antidepressants therapy for both 
PPDC and PDC measures than those covered by a public plan. The proportion of 
patients with a PPDC and PDC >80% (considered as adherent)(28) were 75.8% 
and 62.4% in the privately-insured group compared to 69.4% and 51.8% in the 
publicly-insured group, respectively. Linear regression analysis for the PPDC 
resulted in an adjusted mean difference of 6.7% (95% CI, 3.0 to 10.4) for all users 
and 19.4% (95% CI, 7.5 to 31.3) for incident users in favour of patients privately 
insured (Table 8). The final linear regression model for the PDC measure resulted 
in an adjusted mean difference of 11.4% (95% CI, 7.0 to 15.8) for all users and 
34.4% (95% CI, 23.0 to 45.7) for incident users in favour of patients privately 
insured (data available upon request). 
Persistence rate to antidepressants at one year among incident users was 
49.5% for patients privately insured compared to 18.9% for patients publicly 
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insured; log rank test <0.001 (figure 2). Sensitivity analyses for 45 and 90 days 
grace periods produced similar differences (log rank test <0.001) (data available 
upon request). From the Cox proportional hazard reduced model, we estimated an 
adjusted hazard ratio of 0.48 (95% CI, 0.30 to 0.76) for non-persistence comparing 
patients privately and publicly insured.  
As shown in Figure 3, we found that the average cost of antidepressants per 
patient per month was significantly higher among privately-insured patients [$48.17 
(95% CI, 44.60 to 51.74) compared to $33.72 (95% CI, 32.93 to 34.50)]. This was 
noticeable for SSRI and SNRI subclasses, but not for TCA and other 
antidepressants. Linear regression analysis yielded an adjusted mean difference of 
$14.94 CAD (95% CI, 12.30 to 17.58), which represents a 31.0% increase in cost 
among privately-insured patients compared to publicly-insured patients. Average 
costs for 30-day prescriptions of specific antidepressants are presented in Figure 
4. The cost of most individual drugs for both generic and brand names was 
significantly more expensive for privately-insured patients than publicly-insured 
patients, but the greater differences were observed in generic drugs. Finally, we 
found that at cohort entry, 69.4% of publicly-insured patients were prescribed a 
generic antidepressant compared to 53.1% for privately-insured patients (p 
value<0.001). During follow-up, the corresponding figures were 74.5% and 61.3%, 
respectively (p-value<0.001). 
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5.5 Discussion
Our study indicates that patients covered by a private drug insurance plan 
were more adherent to antidepressants than patients under a public drug 
insurance plan. This difference was even more pronounced among incident users 
of antidepressants. Persistence to antidepressants was also significantly higher at 
one year for patients privately insured. In addition, we found that generic use was 
higher in the public group, and patients with private drug insurance paid more for 
their antidepressants.  
Our adherence results found among incident users of antidepressants are 
similar to estimates reported in the literature. Recent American studies on 
privately-insured patients have found rates of adherence to antidepressants 
ranging from 42% to 51%.(11;12) The overall persistence rate at one year was 
found to be 15.6% for the publicly-insured group in our study, which is lower than 
previous findings on persistence to antidepressants in a quite comparable publicly-
insured population (28.4%).(4) This difference in persistence is possibly due to the 
latter study including elderly patients who have been shown to be more persistent 
than younger patients.(18)   
The differences in adherence and persistence rates observed between 
patients privately and publicly insured may be due to differences in deductibles and 
co-payments between the two groups. Although overall drug cost was higher for 
the private group, the amount paid by the patient at the pharmacy when a 
medication is dispensed may be higher for patients publicly insured due to the fixed 
32% co-payment and the monthly $16 deductible, factors that have been shown to 
impact adherence and persistence to antidepressants.(17) Furthermore, 
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workplaces that offer private insurances often have mechanisms in which they 
ensure that their employees seek appropriate medical and psychological treatment 
and comply with the treatment plans to ensure a faster return to work.(29)  
As for costs, the RAMQ’s public drug insurance plan has fixed prices set for 
pharmacist honoraries, which is not the case for private insurers and this might 
explain, at least in part, the higher cost of medications paid by patients privately 
insured. Moreover, the RAMQ’s public drug insurance plan applies the method of 
the “lowest available price” in Canada, which means that the reimbursement is 
based on the lowest priced drug available.(30) This most likely explains the higher 
generic utilization in the publicly-insured group.   
However, the results of this study should be interpreted in light of the 
following limitations. The exposure to antidepressants was based on dispensed 
prescriptions and it does not necessarily represent the actual intake of the 
medications. In addition, there is a possible volunteer bias for privately-insured 
individuals being that we actively recruited patients for the privately-insured group 
and not for the publicly-insured group. This can lead to overestimating adherence 
and persistence in the private group and thus overestimating the differences 
between these two groups. Even if present, the magnitude of this bias is likely to 
be limited due to the recruitment of patients at a high rate (77%) in reMed. 
Furthermore, the possibility of residual confounding cannot be dismissed due to 
unmeasured variables such as the specialty of prescribing physician, visits to 
psychologists, family income and level of education, which has been shown to be 
associated with adherence and persistence to antidepressants in several 
studies.(4;13;31)  It is worth noting that only patients with low levels of income 
were found to be less persistent to antidepressants while those who were 
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considered to have a medium level income did not significantly differ in persistence 
from patients with high income levels.(31) In order to minimize the impact of socio-
economic differences between patients privately and publicly insured, we restricted 
the study to workers and their families, and we matched on the area of residence. 
If socio-economic differences are still present between patients with private and 
public drug insurance they are likely to be small and should not have a major 
impact on treatment adherence and persistence. Finally, the study’s external 
validity is limited to workers and their families and one should be careful in 
generalizing to other populations.   
Despite these limitations, this study has several strengths. This is the first 
Canadian study to compare adherence, persistence and cost of antidepressants 
between patients privately and publicly insured for their medications. Furthermore, 
by comparing patients with private drug insurance to workers and their families 
covered by the public drug insurance and not including patients who received 
social assistance, we minimized socio-economic differences between the groups. 
Our multivariate analyses also took into account the presence of co-morbidities in 
the year prior to cohort entry, which helped minimize confounding bias. In addition, 
the RAMQ and reMed databases include data on prescribed medications that have 
been collected prospectively and that have been validated.21 Finally, the use of 
the PPDC measure provided us with a more precise measure of patient’s 
adherence.  
Adherence and persistence, particularly among incident users of 
antidepressants, remain suboptimal in the province of Quebec. Our study also 
showed that there were large differences between the compared groups, with 
patients privately insured starting an antidepressant therapy being close to 20% 
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more adherent than patients publicly insured, despite the fact that the cost of the 
medication was higher for patients privately insured. Difference in adherence might 
be explained by higher co-payment for patients with public drug insurance, while 
difference in cost is likely explained by dispensing fees that are fixed by the public 
insurer and not restricted by private insurers. Lastly, our study shows that it is 
important to include both patients with private and public drug insurance in drug 
use studies since they have different behaviours. 
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Table 6. Comparison of characteristics between patients with private and public drug 
insurance
Privately-insured 
patients 
Publicly-insured 
patients 
n (%) n (%) p-value 
Number of patients 194 (100.0) 1923 (100.0)  
Measured at cohort entry 
Age group (years) 
20-34 
35-49 
50-64 
29 (14.9) 
76 (39.2) 
89 (45.9) 
289 (15.0) 
759 (39.5) 
875 (45.5) 
0.995 
Male 41 (21.3) 454 (23.6) 0.438 
Antidepressant subclasses
1
SSRI  
SNRI  
TCA  
 Other 
86 (44.3) 
61 (31.4) 
27 (13.9) 
20 (10.3) 
872 (45.4) 
485 (25.2) 
301 (15.7) 
265 (13.8) 
0.203 
Incident users of antidepressants 36 (18.6) 220 (11.4) 0.004 
In the year before cohort entry
≥ 1 hospitalization (all causes) 22 (11.3) 205 (10.7) 0.771 
>1  emergency department visit (all causes) 55 (28.4) 464 (24.1) 0.193 
Ambulatory medical visits (all causes) (mean ± 
SD) 
8.8 ± 10.4 7.3 ± 7.5 0.058 
Mental health diagnoses 
Depression  50 (25.8) 469 (24.4) 0.669 
Anxiety or adjustment disorders 65 (33.5) 618 (32.1) 0.698 
Other diagnoses2 46 (24.9) 474 (24.6) 0.773 
Filled prescription for the treatment of       
Hypertension 33 (17.0) 304 (15.8) 0.663 
Dyslipidemia 35 (18.0) 372 (19.3) 0.661 
Cardiovascular diseases  13(6.7) 133 (6.9) 0.910 
Diabetes 14 (7.2) 132 (6.7) 0.854 
Respiratory diseases 40  (20.6) 321 (16.7) 0.166 
Gastrointestinal diseases 46 (23.7) 391 (20.3) 0.268 
Inflammation 66 (34.0) 462 (24.0) 0.002 
Measured during follow-up (up to 1  year)
Follow-up duration (days: mean ± SD) 333.8 ± 73.8 357.2 ± 31.7 <0.001 
Switch between sub-classes of antidepressants 24 (12.4) 168 (8.7) 0.093 
1
 SSRI: selective serotonin reuptake inhibitors; SNRI: Selective norepinephrine reuptake inhibitors; 
TCA: Trycyclic antidepressants; Other: Bubropion, Nefazodone, Mirtazapine, Trazodone  
Moclobemide, Phenelzine and Tranylcypromine  
2
Schizophrenia, bipolar disorder, persistent delusional disorders, alcohol dependence syndrome, 
drug dependence, non-dependent abuse of drugs, sleep disorders, suicide and self inflicted injury 
and migraines. 
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Table 7. Adherence to antidepressants up to one year 
Privately-
insured patients 
Publicly-insured 
patients 
Mean ± SD⁴  Mean ± SD⁴ Mean 
difference 
p-value 
Number of users of anti-
depressants 194  1923 
Proportion of days prescribed ¹ 88.2 ± 22.7 81.5 ± 27.7 6.7 <0.001 
PPDC² 86.4 ± 21.8 81.3 ± 26.6 5.1 0.003 
PDC³ 76.2 ± 28.1 67.5 ± 33.3 8.7 0.001 
Number of incident users of 
antidepressants 36  220  
Proportion of days prescribed ¹ 78.8 ± 31.4 55.1 ± 35.9 23.7 <0.001 
PPDC² 78.4 ± 30.2 59.0 ± 34.2 19.4 0.002 
PDC³ 61.2 ± 36.6 30.3 ± 31.3 30.9 <0.001 
¹ Proportion of days prescribed ¹=Total number of days prescribed by physicians divided by the 
number of days of follow-up 
² PPDC= Proportion of prescribed days covered 
 ³ PDC=Proportion of days covered  
⁴SD= Standard deviation  
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Table 8. Association between insurance status and adherence to antidepressants measured 
with the PPDC  
 Final model 
All users of antidepressants 
Final model 
Incident users of antidepressants 
Variables Mean PPDC 
difference 
(%) 
 95% CI Mean PPDC 
difference 
(%) 
 95% CI 
Private versus public drug 
insurance 
6.7 (3.0; 10.4) 19.4 (7.5; 31.3) 
Age at cohort entry 
18-34  
34-49 
50-64 
NR NR 
Female versus male 2.6 (0.1; 5.2) NR  
Cohort entry in 2009 versus 
2007-2008 
3.8 (0.9; 6.7) NR 
Incident versus prevalent 
users of antidepressants  
23.0 (19.7; 26.3) Not included in 
the full model 
Filled prescription for the 
treatment of   cardiovascular 
diseases  
5.7 (1.5; 9.9) NR  
Other indications -2.7 (-5.1;-0.2) NR  
Abbreviations: NR: Not retained in the final model; PPDC= Proportion of prescribed days covered 
SSRI: selective serotonin reuptake inhibitors; SNRI: Selective norepinephrine reuptake inhibitors; 
TCA: Trycyclic antidepressants; Other: Bubropion, Nefazodone, Mirtazapine, Trazodone  
Moclobemide, Phenelzine and Tranylcypromine 
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Number of incident users persistent 
90 days
n (%) 
180 days
n (%) 
270 days
n (%) 
365 days
n (%)  
Log rank p-value
Insurance status
Private n=36 (reMed) 
Public n=220 (RAMQ) 
22 (61.1) 
73 (33.2) 
22 (61.1) 
52 (23.9) 
17 (49.5) 
42 (19.5) 
16 (45.4) 
34 (15.6) 
<0.001
Figure 2. Persistence to antidepressants up to one year
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Figure 3. Average cost of antidepressants per patient per month up to one 
year of treatment 
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Figure 4. Percent cost difference for a 30-day prescription of antidepressants 
between patients with private and public drug insurance
 Brand name antidepressants
 Generic antidepressants
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Chapter 6: Supplemental results 
This chapter is a supplement to the results presented in the manuscript. 
Results presented in the manuscript are not presented in this chapter. 
6.1 Adherence and persistence 
Table 9 presents the proportion of days prescribed, PPDC and PDC for 
individual antidepressant subclasses. The PDC for the SSRI and SNRI classes 
were significantly higher in the privately insured group, 80.3% vs. 71.5% and 
84.0% vs. 74.6%, respectively. Only the PPDC for the SNRI classes was 
significantly different, 89.6% in the private group compared to 84.1% in the public 
group. The PDC and PPDC for the TCA and Other antidepressants were not 
statistically different between insurance groups.   
Crude, adjusted and final models for incident users of antidepressants for 
the PDC measure of adherence is presented in table 10. After adjustment of all 
significant confounders, the linear regression produced a mean difference of 34.4% 
(95% CI 23.0-45.7) in favor of the privately insured group.  
Persistence to antidepressants for up to 2 years is presented in table 11 and 
in figure 5. At 18 months 37.8% in the private group remained persistent versus 
12.5% in the public group. At 24 months 9.3% remained persistent in the public 
group and none in the private group. 
Regression analysis for crude adjusted and final models of average cost per 
patient month is presented in table 12. Mean difference was 14.45$ (95% CI 11.73; 
17.16) for cost favoring the privately insured group, however after adjustment of all 
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variables the mean difference was 14.95$ (95% CI 12.28; 17.59). Lastly the final 
model contained yielded a mean differences of 14.94$ (95% CI 12.30; 17.58) being 
more expensive for those privately insured. 
6.2 Subgroup analyses 
Linear regression analysis for the PDC of the SSRI class produced a 
statistically significant mean difference of 9.0 (95% CI: 2.4; 15.6) favoring those 
privately insured, (Table 13) however the mean difference for the PPDC was not 
significant 3.4 (95% CI: -2.1; 8.9). (Table 14) 
Linear regression analysis for the PDC of the SNRI class produced a 
statistically significant mean difference of 10.7 (95% CI: 2.1; 19.2) in favor of the 
private insured group as shown in Table 15. Lastly, the mean difference for the 
PPDC was not significant, 5.8 (95% CI: -1.1; 12.7). (Table 16) 
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Chapter 7: Discussion  
This chapter presents additional discussion on the results presented in the 
manuscript, as well as the supplemental results presented in Chapter 6. This 
discussion is organized according to the three objectives covered in this thesis, 
namely, adherence, persistence, and cost of antidepressants between private and 
publicly insured individuals. The Chapter will then end with a discussion of the 
clinical impact of the results, and their relevance to healthcare policy and future 
research. 
7.1 Adherence to antidepressants 
Overall, our study indicates that patients covered by a private drug insurance 
plan are more adherent to antidepressant therapy than patients under a public drug 
insurance plan. Using the PDC and PPDC, we were able to measure adherence 
over a one year period, with rates of 76.2% and 86.4% for those privately insured 
compared to 67.5% and 81.3% for publicly insured with the RAMQ program, 
respectively. Interestingly, adherence was considerably lower in new users of 
antidepressants, regardless of insurance program. However, adherence was much 
higher in terms of PDC and PPDC in privately insured patients compared to the 
publicly insured patients for such patients (mean differences: 34.4% and 19.4%, 
respectively). While it is known that incident users are those less likely to be 
adherent to a given therapy, our study indicates that insurance status (i.e. private 
versus public) is also an important determinant of adherence. As such, treating 
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physicians should be aware of this fact, and perhaps be more vigilant with patients 
publicly insured for their medications. Furthermore, it is clear from this study, at 
least for the Quebec population, that adherence rates in privately and publicly 
insured patients are not interchangeable.  
When comparing our adherence results to those published in other studies, it 
appears that our adherence rate is higher. Recent US studies on privately insured 
patients have indeed found lower rates of adherence to antidepressants ranging 
from 42%-51%.57,95 However, it is important to note that there are varying levels of 
private medical coverage in the US. It is possible that in certain private US drug 
plans, patients minimize their claims as to not exceed their annual maximums. 
Furthermore, drugs are typically more expensive than in Canada, resulting in a 
higher co-payment, and thus potentially resulting in a lower adherence. Future 
research should focus on factors that can explain the discrepancies in adherence 
rates between Quebec and the US. 
7.2 Persistence to antidepressants 
In this study, one-year persistence rates to antidepressants were also 
significantly higher for patients privately insured compared to patients publicly 
insured, 49.5% versus 18.9%, respectively. Our low persistence rate of 18.9% for 
publicly insured patients was lower than what was reported in a recent study 
conducted within the RAMQ population, which was reported to be 28.4%.21
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However, in contrast to our study, the previous RAMQ study included elderly 
patients, which have been shown to be more persistent than younger patients.84
While it is known that persistence to antidepressants in particular is low, the 
differences observed between publicly and privately insured patients is remarkable. 
As with adherence, our results highlight the importance of not interchanging these 
two subpopulations when investigating persistence to antidepressants. Thus, 
treating physicians should be aware of this fact, and perhaps be more vigilant with 
patients publicly insured for their medications. While this study focused on 
antidepressants, it is possible that such differences also exist with other 
pharmacotherapies. Given the large differences in persistence rates, future 
research should make a distinction between these two patient populations when 
investigating persistence. 
7.3 Costs of antidepressants 
As expected, average cost of antidepressants per patient per month was 
significantly higher for privately insured patients. Overall, those privately insured 
spent $14.45 more per month for their antidepressants than those insured under 
the RAMQ drug insurance plan. These price differences were comparable for the 
SSRI and SNRI classes as well.  
Individual drug cost for 30-day prescriptions were more expensive for those 
under a private drug insurance plan. This was apparent for the SSRI and SNRI 
classes, but not so for the TCA and other classes. The latter drug classes are older 
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than the SSRI and SNRI classes, and are therefore no longer under a patent. As 
such, we expect the use of generics to be non-differential between publicly and 
privately insured patients, thus not affecting the amount spent. That being said, 
generic use was higher in publicly insured patients, both at cohort entry and during 
follow up.  
7.4 Clinical significance  
Adherence and persistence to antidepressants was found to be suboptimal 
in the province of Quebec, particularly among new users of antidepressants. This 
problem appears to be more pronounced among patients covered by the public 
insurance program. While such results raise concerns, clinicians and pharmacists 
should be aware of this issue, in order to better identify patients who are likely to 
become non-adherent and non-persistent to antidepressants, and thus stress the 
importance of maintaining optimal dose while continuously using the drug for the 
entire prescribed length. 
7.5 Reasons for differences in the three measured outcomes between 
publicly and privately insured patients 
The differences in adherence and persistence rates observed between 
patients privately and publicly insured may be due to differences in deductibles, co-
payments, and reimbursement policies between the two groups. Although overall 
drug cost was more expensive for the private group, the amount paid by the patient 
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at the pharmacy when a medication is dispensed may be higher for patients 
publicly insured due to higher co-payments and deductibles, factors that have been 
shown to impact adherence and persistence to antidepressants.88 Furthermore, 
companies which offer private insurances often have mechanisms in which they 
ensure that their employees seek appropriate medical and psychological treatment 
and comply with the treatment plans to ensure a faster return to work.96
As for reasons explain these differences in drug costs, the RAMQ has fixed 
the honoraria of pharmacists, whereas such honoraria fixing is not present with 
private drug plans. Therefore the cost of a particular drug may be significantly 
higher for a privately insured patient compared to a publicly insured patient. 
Moreover, the RAMQ applies the method of the “lowest available price” in Canada, 
which means that the reimbursement is based on the lowest priced drug 
available.97 This most likely explains the higher generic use in the publicly insured 
patients. Furthermore, our findings on cost and generic utilization are in line with 
previous studies, demonstrating lower pharmacy costs when initiating treatment 
with a generic medication.98
7.6 Limitations 
While our study produced some interesting findings, certain limitations need 
to be considered. There is a possible volunteer bias for privately-insured 
individuals being that we actively recruited patients for the privately-insured group 
and not for the publicly-insured group. The patients who accepted may have been 
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more health-conscious and adherent to therapy than those who did not accept to 
be included in the reMed project. This can lead to overestimate adherence and 
persistence in the private group and thus overestimate the differences between the 
two groups. Even if present, the magnitude of this bias is likely to be limited due to 
the recruitment of patients on all drug classes at a high rate (77%) in reMed. 
Exposure to antidepressants was based on dispensed prescriptions, which 
may not necessarily reflect actual intake. As a result, it may have overestimated 
our adherence and persistence rates, by misclassifying non-exposure as exposure. 
However, continually refilling prescriptions on time is a reasonable indicator that 
patients were in fact adherent and persistent. Patients were deemed persistent if 
they refilled their antidepressant prescription within a 60-day grace period. This 
grace period may have overestimated persistence if the patient had in fact 
terminated the treatment, although sensitivity analyses using alternate grace 
periods of 45 days and 90 days did not significantly change the results. In addition, 
drug prescriptions were used as proxies of comorbidities, and it is therefore 
possible that this method may have missed individuals diagnosed with disease but 
not yet treated for it.
Furthermore, the reMed and RAMQ databases did not include the indication 
for which the antidepressants were prescribed. These drugs are now prescribed for 
a wide range of indications, ranging from anxiety to migraines.21 As such, the 
duration and dose of therapy is not expected to be same across all these 
indications. In terms of adherence, this is more of a concern for PDC, since it does 
not take into account the duration intended by the prescribing physician. However, 
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this is less of a concern for PPDC which takes into account the intended duration 
of the prescription, which was one of the motivating reasons why we chose to use 
this measure as well. Furthermore, because antidepressants are prescribed for 
numerous indications which may differentially affect our study outcomes, we 
attempted to control for confounding by indication by adjusting the models with the 
major indications for antidepressant use, namely, depression, anxiety, or other 
conditions. While most patients fall into the depression/anxiety categories, residual 
confounding by indication is still possible. 
As with any observational study, it is not possible to fully eliminate residual 
confounding from unmeasured variables. Such unmeasured potential confounders 
include the specialty of the prescribing physician for example, which was not 
available in the reMed database. This is a variable of interest, since patients 
treated by psychiatrists have been shown to have better adherence and 
persistence compared to patients treated by general practitioners.21,65 Furthermore, 
other potential confounders which were not measured are those of psychosocial 
nature such as beliefs and attitudes towards pharmacotherapy in particular in 
depression and those related to the disease such as duration of treatment. 
Moreover, we did not have data on visits to psychologists which has been shown to 
affect treatment adherence.21 It is possible that privately-insured patients had 
better access, through their insurance, to psychologists or other mental health 
professionals. While this may have occurred, this missing variable would have to 
be greatly differential between the insurance groups and strongly associated with 
adherence and persistence to substantially alter the results.  
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The precision and statistical power of our study was very strong. However, 
stratification by incident use and antidepressant subclass resulted in smaller 
number of exposed patients thereby affecting statistical power. Finally the study’s 
external validity was limited to workers and their families in Quebec, and therefore 
these results should not be generalized to the general population.  
7.6 Strengths 
Despite these limitations, this study had several strengths. To our 
knowledge, this is the first study to compare adherence, persistence and cost of 
antidepressants between patients privately and publicly insured for their 
medications. The matching on age, sex, CLSC territory, and index date at the 
design stage led to limiting confounding bias. Furthermore, we tried to further 
minimize socio-economic differences by comparing patients with private drug 
insurance to the RAMQ “adherents” (i.e. workers and their families who do not 
receive social assistance). Our multivariate analyses adjusted for a number of 
potential confounders, in an effort to further reduce confounding. Moreover, the 
RAMQ and reMed databases include data on prescribed medications that have 
been collected prospectively and that have been validated.  
7.7 Conclusion 
Antidepressants are widely prescribed in Canada and particularly in 
Quebec. While guidelines stress the importance of maintaining antidepressant use 
at optimal levels and duration to achieve clinical benefit,50 we found low adherence 
and persistence rates, representing a significant problem in management of 
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depressive disorders further contributing to the economic burden of these 
diseases.  
The findings on adherence and persistence are consistent with many 
studies which have shown inadequate rates of adherence and persistence for new 
users of antidepressants across different population settings.21,57,95 The PPDC 
adherence measure used in this study corrected for the prescribing patterns 
without having to consult patient medical records. This was a major strength and 
gave us greater insight on patient behavior towards antidepressants.  
This study provides insight into Quebec’s public and private medication 
insurance plans, an area of research that remained understudied. With respect to 
antidepressants, while it was not a surprise to observe cost differences, future 
research is needed to better understand patient adherence and persistence rates 
between public and private drug insurance programs. Furthermore, it would be 
interesting to examine if these differences are present in other chronic drug 
classes. This can be done using reMed since the database includes patients 
exposed to diverse drug classes. Finally, the next step will be to associate 
adherence and persistence rates to clinically relevant outcomes, such as relapse 
and disease progression in both publicly and privately insured patients. 
In summary, adherence and persistence to antidepressants was suboptimal 
in the province of Quebec particularly for new users of antidepressants. This 
problem appears to be exacerbated by being covered by public insurance program. 
While such results raise concerns, they should also raise awareness of the 
potential differences that may exist between patients belonging to different 
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insurance programs. Additional research is needed to understand these 
differences, which can then be translated into clinical practice. This can be through 
patient education of the benefits of antidepressant therapy, and providing treating 
physicians with better tools to identify patients at risk of being non-adherent and 
non-persistent. Ultimately, this study can be the stepping stone for a broader 
research program focused on the use of different types of drugs in other indications 
between publicly and privately insured patients. Improving adherence and 
persistence to medications in susceptible populations is likely to highly impact 
clinical effectiveness. 
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Chapter 9: Supplemental tables & figures 
This section presents the additional results discussed in the thesis which 
were not presented in the manuscript.  
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Table 9. Adherence to antidepressants by subclass
 Privately-insured patients Publicly-insured patients 
Mean difference p-value 
 mean ± SD mean ± SD 
SSRI 
Number of patients 86  872    
Proportion of days prescribed (%)¹ 92.1 ± 17.2 84.4 ± 24.9 7.7 <0.001 
PPDC²  87.4 ± 20.2 83.7 ± 24.1 3.7 0.120 
PDC³  80.3 ± 24.3 71.5 ± 30.5 8.8 0.002 
SNRI     
Number of patients 61 484   
Proportion of days prescribed (%)¹ 94.1 ± 11.7 84.8 ± 25.6 9.3 <0.001 
PPDC²   89.6 ± 17.4  84.1 ± 25.9  5.5 0.031 
PDC³   84.0 ± 18.8 72.6 ± 32.5 11.4 <0.001 
TCA     
Number of patients 27  301   
Proportion of days prescribed (%)¹ 78.6 ± 34.4 77.0 ± 31.7 1.6 0.806 
PPDC²   77.8 ± 31.5  73.3 ± 31.8  4.5 0.483 
PDC³   59.6 ± 39.0  57.1 ± 36.6  2.5 0.733 
Other     
Number of patients 20 265   
Proportion of days prescribed (%)¹ 79.3 ± 30.2 73.2 ± 33.0 6.1 0.425 
PPDC²  76.4 ± 28.9  77.7 ± 28.6  -1.3 0.843 
PDC³   62.3 ± 35.7  59.1 ± 36.9  3.2 0.708 
¹ Proportion of days prescribed (%) ¹=number of days prescribed by physician divided by follow up 
² PPDC= Proportion of prescribed days covered 
³ PDC=Proportion of days covered
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Table 10. Association between insurance group status and adherence to antidepressant agents measured with the 
PDC among incident users 
Crude Adjusted Final model 
Variables 
Mean 
difference 
(%) 
95% CI 
Mean 
difference 
(%) 
95% CI 
Mean 
difference 
(%) 
95% CI 
Insurance status
Private 30.8 (19.5, 42.2) 32.5 (20.2, 44.8) 34.4 (23.0, 45.7) 
Public reference  reference  reference  
Age group at index date
18-34  reference      
34-49 2.7 (-8.6, 14.0) 0.8 (-10.2, 11.8) NR  
50-64 3.1 (-8.7, 14.9) -0.5 (-12.4, 11.4) NR  
Sex
Male reference      
Female  -1.8 (-11.7, 8.0) -5.2 (-15.0, 4.5) NR  
Year of cohort entry
2007-2008 reference  reference    
2009 10.9 0.6, 21.3) 5.9 (-4.4, 16.3) NR  
Indication
Depression 3.6 (-7.1, 14.4) 0.4 (-10.1, 10.9) NR  
Anxiety 5.1 (-3.8, 14.0) 3.9 (-4.8, 12.5) NR  
Others 3.3 (-5.6, 12.1) 1.2 (-7.7, 10.1) NR  
Comorbidities in the year 
prior to index date 
Hypertension -2.9 (-18.1, 12.3) -17.4 (-34.3, -0.5) -17.5 (-32.9, -2.1) 
Dyslipidemia 7.1 (-5.0, 19.2) 2.2 (-11.6, 15.9) NR  
Other cardiovascular 
diseases  
18.5 (-0.3, 36.7) 24.9 (4.1, 45.7) 29.1 (10.6, 47.6) 
Diabetes 7.8 (-14.8, 30.4) 3.9 (-20.0, 27.9) NR  
Respiratory diseases -7.3 (-19.4, 4.8) -14.7 (-26.4, -3.0) -12.6 (-24.0, -1.1) 
Gastro intestinal diseases 9.5 (-1.6, 20.6) 8.5 (-2.8, 19.8) NR  
Inflammation 4.2 (-4.8, 13.1) -1.1 (-10.3, 8.0) NR  
Use of any healthcare 
services in the year prior to 
index date 
≥1 hospitalization 9.1 (-3.6, 21.9) 7.3 (-6.0, 20.5) NR  
≥1 emergency department 
visits  
-3.7 (-12.8, 5.5) -8.1 (-17.4, 1.2) NR  
Outpatients medical visits   0.5 (-0.1, 1.2) 0.3 (-0.5, 1.1) NR  
NR: Variable not retained in the final model. 
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Table 11. Persistence rate for all antidepressants according to duration of follow-up n (%) 
Insurance status 3 months 6 months 9 months 12 months 18 months 24 months 
Log rank
p-value 
Private (reMed) (n=36) 22 (61.1) 22 (61.1) 17 (49.5) 16 (45.4) 13 (37.8) - 
<0.001
Public (RAMQ)  (n=220) 73 (33.2) 52 (23.9) 42 (19.5) 41 (18.9) 27 (12.5) 20 (9.3) 
P a g e  | 105 
 Figure 5. Kaplan-Meier curve displaying persistance to antidepressants 
according to drug insurance status after 2 years of follow-up
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Table 12. Average cost in Canadian dollars of antidepressants per patient per month
Crude Adjusted Final model 
Variables 
Mean 
difference 
($) 
95% CI 
Mean 
difference 
($) 
95% CI 
Mean 
difference 
($) 
95% CI 
Insurance status
Private 14.45 (11.73, 17.16) 14.93 (12.28, 17.59) 14.94 (12.30, 17.58) 
Public reference  reference  reference  
Age group at index date
18-34  reference  reference    
34-49 -0.20 (-2.64, 2.24) -0.17 (-2.51, 2.17) NR  
50-64 -1.12 (-3.51, 1.27) -1.10 (-3.50, 1.31) NR  
Sex
Male reference  reference    
Female  -1.20 (-3.10, 0.70) -1.65 (-3.40, 0.20) NR  
Year of cohort entry
2007-2008 reference  reference    
2009 -1.19 (-3.37, 0.99) -0.49 (-2.56, 1.58) NR  
Incident use of 
antidepressants 
9.02 (6.59, 11.46) 9.39 (7.02, 11.26) 9.22 (6.87, 11.56) 
Indication
Depression 6.68 (4.83, 8.53) 6.03 (4.21, 7.84) 6.04 (4.27, 7.81)) 
Anxiety 4.23 (2.52, 5.94) 3.86 (2.21, 5.52) 4.06 (2.44, 5.69) 
Others -3.14 (-5.00, 1.27) -2.42 (-4.26, -0.59) -2.29 (-4.06, -0.52 
Comorbidities in the year 
prior to index date 
Hypertension -0.27 (-2.47, 1.93) -0.08 (-2.48, 2.32) NR  
Dyslipidemia 0.20 (-1.84, 2.24) 1.58 (-0.72, 3.87) NR  
Other cardiovascular 
diseases  
-2.06 (-5.24, 1.11) -1.69 (-4.85, 1.46) NR 
Diabetes -0.91 (-4.08, 2.27) -1.74 (-5.16, 1.68) NR  
Respiratory diseases 0.94 (-1.20, 3.08) 0.52 (-1.56, 2.60) NR  
Gastro intestinal diseases 0.59 (-2.57, 1.40) 0.48 (-2.50, 1.53) NR  
Inflammation -0.46 (-2.31, 1.40) 0.11 (-1.72, 1.95) NR  
Use of any healthcare 
services in the year prior to 
index date 
≥1 hospitalization 0.29 (-2.31, 2.89) -0.59 (-3.24, 2.05) NR  
≥1 emergency department 
visits  
1.58 (-0.29, 3.45) 1.48 (0.43, 3.39) NR 
Outpatient medical visits   0.07 (-0.03, 0.18) 0.00 (-0.11, 0.11) NR  
NR: Variable not retained in the final model 
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Table 13. Association between insurance group status and adherence to antidepressant agents measured with the 
PDC among SSRI users (n=958)
Crude Adjusted Final model
Variables Mean 
difference 
(%)
95% CI Mean 
difference 
(%)
95% CI Mean 
difference 
(%)
95% CI
Insurance status
Private 7.7 (0.8; 14.6) 9.5 (2.9; 16.0) 9.0 (2.4; 15.6) 
Public reference  reference  reference  
Age group at index date
18-34  reference  reference    
34-49 3.5 (-2.3; 9.3) 1.0 (-4.6; 6.6) NR  
50-64 10.7 (5.0; 16.4) 5.3 (-0.5; 11.0) NR  
Sex
Male  
Female 
reference 
0.7 (-4.1; 5.5) 
reference 
1.7 (-2.9; 6.4) 
NR  
Year of cohort entry
2007 or 2008 reference  reference    
2009 1.7 (-3.8; 7.2) 3.1 (-2.1; 8.3) NR  
Incident use of 
Antidepressants 
34.8 (27.4; 42.2) 32.6 (25.2; 40.0) 35.2 (27.8; 42.6) 
Indication
Depression 
Anxiety  
Others 
-6.9 
-6.4 
-3.9 
(-11.4; -2.4) 
(-10.6; -2.2) 
(-8.9; 1.1) 
-6.5 
-4.2 
-2.8 
(-10.9; 2.2) 
(-8.3; 0.2) 
(-7.7; 2.1) 
NR 
NR 
NR 
Comorbidities
Hypertension 8.7 (3.3; 14.1) 0.1 (-5.9; 6.1) NR  
Dyslipidemia 10.7 (5.8; 15.6) 4.5 (-1.2; 10.2) NR  
Cardiovascular diseases 
(other) 
14.6 (6.9; 22.3) 9.5 (9.5; 17.3) NR  
Diabetes 8.7 (1.4; 16.0) 1.2 (-7.0; 9.3) NR  
Respiratory  diseases 1.7 (-3.6; 6.9) -1.7 (-6.8; 3.4) NR  
Gastro intestinal diseases 3.7 (-1.3; 8.7) -0.5 (-5.6; 4.7) NR  
Inflammation -0.2 (-4.9; 4.6) -0.8 (-5.6; 3.9) NR  
Use of any healthcare 
services in the year prior 
to index date
≥1hospitalization -0.1 (-6.4; 6.1) -0.1 (-6.6; 6.3) NR  
≥1 emergency department 
visits -3.5 (-8.2; 1.2) -1.1 (-5.9; 3.8) NR 
outpatient medical visits   -0.1 (-0.3; 0.2) 0.0 (-0.3; 0.2) NR  
NR: Variable not retained in the final model 
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Table 14. Association between insurance group status and adherence to antidepressant agents measured with the 
PPDC among SSRI users (n=958) 
Crude Adjusted Final model
Variables Mean 
difference 
(%) 
95% CI Mean 
difference 
(%) 
95% CI Mean 
difference 
(%) 
95% CI
Insurance status
Private 2.5 (-3.2; 8.2) 3.9 (-1.5; 9.5) 3.4 (-2.1; 8.9) 
Public reference  reference  reference  
Age group at index date
18-34 reference  reference  reference  
34-49 4.6 (-0.1; 9.4) 3.0 (-1.7; 7.8) NR  
50-64 7.0 (2.3; 11.7) 4.1 (-0.8; 9.0) NR  
Sex
Male  
Female 
reference 
-1.3 (-5.2; 2.6) 
reference 
-0.8 (-4.7; 3.1) 
NR 
Year of cohort entry
2007 or 2008 reference  reference    
2009 1.7 (-2.7; 6.2) 2.8 (-1.6; 7.2) NR  
Incident use of 
Antidepressants 
25.4 (19.3; 31.5) 23.7 (17.5; 29.9) 25.5 (19.4; 31.6) 
Indication
Depression
Anxiety  
Others 
-2.5 
-3.9 
-4.6 
(-6.1; 1.2) 
(-7.3; -0.4) 
(-8.7; 0.5) 
-2.5 
-2.4 
-3.5 
(-6.2; 1.2) 
(-5.8; 0.9) 
(-7.6; 0.6) 
NR 
NR 
NR 
Comorbidities
Hypertension 4.1 (-0.3; 8.6) -1.2 (-6.2; 3.9) NR  
Dyslipidemia 5.2 (1.2; 9.2) 1.0 (-3.9; 5.8) NR  
Cardiovascular      
diseases (other) 
8.2 (1.9; 14.5) 5.5 (1.1; 12.0) NR  
Diabetes 6.3 (0.3; 12.3) 2.5 (-5.7; 10.7) NR  
Respiratory  diseases 4.2 (-0.1; 8.5) 2.3 (-2.0; 6.6) NR  
Gastro intestinal diseases 1.7 (-2.3; 5.9) -0.6 (-4.9; 3.7) NR  
Inflammation -2.0 (-5.9; 1.9) -2.1 (-6.0; 1.9) NR  
Use of any healthcare 
services in the year prior 
to index date
≥1hospitalization -1.0 (-6.1; 4.2) -0.6 (-6.0; 4.9) NR  
≥1 emergency department 
visits -2.2 (-6.0; 1.7) -0.6 (-4.6; 3.5) NR 
Outpatient medical visits   0.0 (-0.2; 0.2) 0.0 (-0.2; 0.2) NR 
NR: Variable not retained in the final model 
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Table 15. Association between insurance group status and adherence to antidepressant agents measured with 
the PDC among SNRI  users (n=545) 
Crude Adjusted Final model
Variables Mean 
difference 
(%) 
95% CI Mean 
difference 
(%) 
95% CI Mean 
difference 
(%) 
95% CI
Insurance status
Private 6.4 (-2.3; 15.2) 12.9 (4.3; 21.5) 10.7 (2.1; 19.2) 
Public reference  reference  reference  
Age group at index 
date 
18-34  reference  reference  reference  
34-49 5.1 (-2.9; 13.1) 4.3 (-3.6; 12.1) NR  
50-64 10.7 (2.6; 18.8) 8.5 (0.3; 16.7) NR  
Sex
Male reference  reference    
Female 1.5 (-5.0; 8.1) 5.3 (-1.0; 11.6) NR  
Year of cohort entry
2007-2008 reference  reference    
2009 9.0 (1.8; 16.2) 10.3 (3.4; 17.1) NR  
Incident use of 
Antidepressants 33.1 (22.8; 43.4) 35.9 (25.5; 46.3) 
35.0 (24.6; 45.3) 
Indication
Depression 
Anxiety  
Others 
-9.1 
-0.4 
-4.9 
(-15.2; -3.1) 
(-6.2; 5.4) 
(-11.7; 2.0) 
-8.5 
-0.2 
-2.0 
(-14.4; -2.5) 
(-5.9; 5.4) 
(-8.7; 4.8) 
NR 
NR 
NR 
Comorbidities
Hypertension -3.3 (-11.1; 4.4) -10.8 (-18.7; 2.5) NR  
Dyslipidemia 9.5 (2.1; 16.9) 10.0 (-4.0; 12.5) NR  
Cardiovascular      
diseases (other) 
2.8 (-9.0; 14.6) 3.0 (-6.5; 17.4) NR  
Diabetes 3.8 (-9.3; 16.8) 0.7 (-6.4; 21.0) NR  
Respiratory  diseases 0.1 (-7.5; 7.8) -1.8 (-5.4; 9.5) NR  
Gastro intestinal 
diseases 
3.0 (-4.4; 10.3) 3.0 (-3.8; 11.2) NR  
Inflammation -2.0 (-8.4; 4.4) -1.0 (-6.7; 6.1) NR  
Use of any healthcare 
services in the year 
prior to index date
≥1hospitalization -0.6 (-9.9; 8.8) 4.4 (-5.3; 14.1) NR  
≥1 emergency  
department visits -4.2 (-10.7; 2.3) -3.8 (-10.6; 3.0) NR 
Outpatients medical 
visits   -0.2 (-0.6; 0.2) -0.1 (-0.5; 0.4) NR 
NR: Variable not retained in the final model 
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Table 16. Association between insurance group status and adherence to antidepressant agents measured with 
the PPDC among SNRI users (n=545) 
Crude Adjusted Final model
Variables Mean 
difference 
(%) 
95% CI Mean 
difference 
(%) 
95% CI Mean 
difference 
(%) 
95% CI
Insurance status
Private 
Public 
3.0 
reference 
(-3.9; 10.0) 5.8 
reference 
(-1.3; 12.9) 5.8 
reference 
(-1.1; 12.7) 
Age at index date
18-34  
34-49 
50-64 
reference 
5.6 
6.2 
(-0.7; 12.0) 
(-0.2; 12.6) 
reference 
5.5 
5.4 
(-0.9; 12.0) 
(-1.4; 12.1) 
reference 
NR 
NR 
Sex
Male  
Female 
reference 
-0.5 (-5.6; 4.7) 
reference 
1.4 (-3.8; 6.6) NR 
Year of cohort entry
2007-2008 reference  reference    
2009 8.1 (2.4; 13.7) 8.6 (2.9; 14.3) 9.0 (3.4; 15.6) 
Incident use of 
Antidepressants 
14.5 (6.2; 22.8) 16.9 (8.4; 25.5) 16.2 (7.8; 24.5) 
Indication
Depression 
Anxiety  
Others 
-4.7 
-1.0 
-2.8 
(-9.3; 0.3) 
(-5.6; 3.5) 
(-8.2; 2.6) 
-3.9 
-0.7 
1.7 
(-8.8; 1.0) 
(-5.4; 4.0) 
(-7.3; 3.8) 
NR 
NR 
NR 
Comorbidities
Hypertension -2.0 (-8.1; 4.2) -4.9 (-11.6; 1.8) NR  
Dyslipidemia 2.2 (-3.6; 8.1) 2.1 (-4.7; 9.0) NR  
Cardiovascular      
diseases (other) 
2.2 (-7.2; 11.5) 2.1 (-7.6; 11.9) NR  
Diabetes 1.9 (-8.4; 12.2) 1.4 (-9.8; 12.5) NR  
Respiratory  
diseases 
0.1 (-6.0; 6.1) -0.6 (-6.6; 5.5) NR  
Gastro intestinal 
diseases 
1.7 (-4.0; 7.5) 1.3 (-4.8; 7.5) NR  
Inflammation 0.8 (-4.2; 5.9) 1.2 (-4.0; 6.5) NR  
Use of any 
healthcare services 
in the year prior to 
index date
≥1hospitalization 4.7 (-2.7; 12.2) 7.0 (-0.9; 15.0) NR  
≥1 emergency  
department visits 0.3 (-5.4; 4.8) -0.4 (-6.0; 5.2) NR 
Outpatients medical 
visits   -0.1 (-0.4; 0.2) -0.1 (-0.4; 0.3) NR 
NR: Variable not retained in the final model 
P a g e  | xviii 
Appendix I
List of Antidepressants
Classes Chemical name
Selective serotonine 
reuptake inhibitors (SSRIs) 
Citalopram 
Escitalopram 
Fluoxetine 
Fluvoxamine 
Paroxatine 
sertraline 
Serotonine and 
norepinephrine reuptake 
inhibitors (SNRIs) 
Desvenlafaxine 
Venlafaxine 
Duloxetine 
Tryptophan 
Atypical antidepressants 
Bubropion 
Nefazodone 
Mirtazapine 
Trazodone 
Tricyclics (TCAs) and others 
cyclic antidepressants 
Amitriptaline 
Clomipramine 
Desipramine 
Doxepin 
Imipramine 
Maprotiline 
Nortriptyline 
Trimipramine 
Monoamide oxidase 
inhibitors (MAOIs) 
Moclobemide 
Phenelzine 
Tranylcypromine 
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Appendix II 
List of symptoms for the classification of depression 
1. Depressed mood most of the day nearly every day 
2. Markedly diminished interest or pleasure in most activities most of the day 
3. Significant weight loss or gain or appetite disturbance 
4. Psychomotor agitation or retardation 
5. Iinappropriate guilt; diminished ability to think or concentrate or 
indecisiveness 
6. Recurring thoughts of death, including suicidal ideation 
7. Insomnia or hypersomnia 
P a g e  | xx 
Appendix lll. Classes  ATC used for different comorbidities
Comorbidity Classes  Exceptions  
Hypertension  Renin 
angiotensin 
inhibitors 
C09****  
Calcium channel 
blockers 
C08**** CO8CA05 
Beta blockers C07**** C07AA05,06,07 
C07AB07,09 
C07AG** 
Diuretics  C03**** C03BA08,C03AA01,C03CA02,
C03DA**,CO3CC** 
Hypotensive C02**** C02AA**,C02CC**, 
C02DD**C02KK** 
Urology G04AA01  
Others V03AA01  
Other 
cardiovascular 
diseases 
Cardiovascular 
therapy 
C01****  
Beta blockers C07AA05,06,07
C07AB07,09 
C07AG** 
Diuretics C03BA08 
C03AA01 
C03CA02 
C03DA** 
C03CC** 
Diabetes Anti-diabetics; 
Insulin, analogues 
and 
blood lowering 
drugs 
A10****  
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Anxiety  Anxiolytics N05BA** 
N05BE** 
N05CD** 
N05CD** 
N05BA05 
benzodiazepine N03AE01  
Dyslipidemia Statins C10AA** 
C10AB** 
C10AC** 
C10AD** 
C10AX** 
C10BA** 
C10BX** 
Bile acid 
sequestering   
C10AC**  
Fibrates C10AB  
nicotinic acid A11HA**  
Respiratory 
diseases 
Drugs for 
obstructive 
respiratoiry 
diseases;  
Andrenergics, 
Glucocorticoids, 
Anticholinergics, 
Antiallergic 
agents 
R03****  
Anti-histamines H02**** H02AB01,H02AB08,H02AA02 
Gastrointestinal 
diseases 
Anti-acid 
H2 receptor 
antagonist  
Prostaglandins 
Proton pump 
A02**** A02AA01 
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inhibitors 
Chronic 
inflammation  
Anti-inflammatory;
Butylpyrazolidines
Acetic acid 
derivatives 
Oxicams 
Propionic acid 
derivatives 
Fenamates 
Coxibs 
MO1A**  M01AE12,M01AG01 
